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CHAPTER – I 
INTRODUCTION 
1.1.Diabetes Mellitus 
The Diabetes Mellitus is being one of the five leading causes of deaths and 
debilitating disease in the world. One hundred and fifty million people were suffering 
from diabetes wide reaching, which is almost five times more than the estimates one 
decade ago and it may double in the year 2030 [1]. The development of diabetic 
complications is a major cause of morbidity and mortality and is an ever-increasing 
burden to healthcare authorities in both developed and developing nations. 
Epidemiological studies have confirmed that hyperglycemia is the most important 
factor in the onset and progress of diabetic complications [2]. 
 
Diabetes mellitus or simply diabetes is a chronic metabolic disorder of carbohydrate, 
lipid and protein metabolism characterized by hyperglycemia, glycosurea, 
hyperlipidemia, negative nitrogen balance and sometimes ketonemia due to 
insufficient or complete cessation of insulin synthesis or secretion and/or peripheral 
resistance to insulin action [3]. The hallmark of diabetes mellitus is polyuria-excessive 
urine production, polydipsia-excessive thirst and polyphagia excessive eating [4]. 
 
Diabetes is a condition primarily defined by the level of hyperglycaemia giving rise to 
risk of microvascular damage (retinopathy, nephropathy and neuropathy). It is 
associated with reduced life expectancy, significant morbidity due to specific 
diabetes related microvascular complications,increased risk of macrovascular 
complications (ischaemic heart disease, stroke and peripheral vascular disease), 
and diminished quality of life[5]. The pathogenesis of diabetes mellitus and its 
complications is managed by insulin and oral administration of hypoglycemic drugs 
such as sulfonylureas and biguanides [6]. However, on chronic usage most of these 
agents produced several side effects, including hypoglycemic coma, insulin 
resistance, hyper-sensitivity, cholesterol, jaundice, abdominal pain, anorexia and 
metallic taste [4]. 
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For various reasons in recent years, the popularity of herbal medicines in diabetic 
control has increased. Natural plant drugs are frequently considered to be less toxic 
with lower side effects than synthetic ones [7].Therefore searching herbal product 
with anti diabetic activity possessing fewer side effects receives considerable 
publicity and provides an opportunity to cure this disease [8]. 
 
1.2. CLASSSIFICATION OF DIABETES MELLITUS: 
 
i. Type 1 diabetes mellitus[9]: 
An autoimmune disease in which the immune system mistakenly destroys the 
insulin-making beta cells of the pancreas. It typically develops more quickly than 
other forms of diabetes. It is usually diagnosed in children and adolescents, and 
sometimes in young adults. To survive, patients must administer insulin medication 
regularly. Type 1diabetes used to be called juvenile diabetes and insulin-
dependent diabetes mellitus (IDDM). However, those terms are not accurate 
because children can develop other forms of diabetes, adults sometimes develop 
type 1, and other forms of diabetes can require insulin therapy. A variation of type 1 
that develops later in life, usually after age 30, is called latent autoimmune diabetes 
of adulthood (LADA). Sometimes patients with 
autoimmune diabetes develop insulin resistance because of weight gain or genetic 
factors. This condition is known as double diabetes. 
 
ii. Type 2 diabetes mellitus[10]: 
A disorder of metabolism, usually involving excess weight and insulin resistance. In 
these patients, the pancreas makes insulin initially, but the body has trouble using 
this glucose controlling hormone. Eventually the pancreas cannot produce enough 
insulin to respond to the body’s need for it. Type 2 diabetes is by far the most 
common form of diabetes, accounting for 85 to 95% of cases in developed nations 
and an even higher percentage in developing nations, according to the International 
Diabetes Federation. This disease may take years or decades to develop. It is 
usually preceded by pre diabetes, in which levels of glucose (blood sugar) are above 
normal but not high enough yet for a diagnosis of diabetes. People with pre diabetes 
can often delay or prevent the escalation to type 2 diabetes by losing weight through 
improvements in exercise and diet, as the Diabetes Prevention Program and other 
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research projects have demonstrated. Type 2 diabetes used to be called adult-
onset diabetes and non-insulin-dependent diabetes mellitus (NIDDM). Those 
terms are not accurate because children can also develop this disease, and some 
patients require insulin therapy. 
 
iii. Other specific type (Monogenic diabetes)[10]: 
Diabetes caused by another condition. The many potential sources of secondary 
diabetes range from diseases such as pancreatitis, cystic fibrosis, Down syndrome 
and hemochromatosis to medical treatments including corticosteroids, other 
immunosuppressives, diuretics and pancreatectomy. 
 
iv. Gestational Diabetes Mellitus (GDM)[11]: 
A temporary metabolic disorder that any previously nondiabetic woman can develop 
during pregnancy, usually the third trimester. Hormonal changes contribute to this 
disease, along with excess weight and family history of diabetes. About 4% of 
pregnant women develop gestational diabetes, according to the American Diabetes 
Association.  
 
 
 
Figure 1: Blood sugar levels 
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1.3.INSULIN BIOSYNTHESIS, SECRETION, AND ACTION [12] 
 
Biosynthesis 
Insulin is produced in the beta cells of the pancreatic islets. It is initially synthesized 
as a single chain 86-amino-acid precursor polypeptide, preproinsulin. Subsequent 
proteolytic processing removes the aminoterminal signal peptide, giving rise to 
proinsulin. Proinsulin is structurally related to insulin-like growth factors I and II, 
which bind weakly to the insulin receptor. Cleavage of an internal 31-residue 
fragment from proinsulin generates the C peptide and the A (21 amino acids) and B 
(30 amino acids) chains of insulin, which are connected by disulfide bonds. The 
mature insulin molecule and C peptide are stored together and co-secreted from 
secretory granules in the beta cells. Because C peptide is cleared more slowly than 
insulin, it is a useful marker of insulin secretion and allows discrimination of 
endogenous and exogenous sources of insulin in the evaluation of hypoglycemia. 
Pancreatic beta cells co-secrete islet amyloid polypeptide (IAPP) or amylin, a 37-
amino-acid peptide, along with insulin. The role of IAPP in normal physiology is 
incompletely defined, but it is the major component of the amyloid fibrils found in the 
islets of patients with type 2 diabetes, and an analogue is sometimes used in treating 
type 1 and type 2 DM. Human insulin is produced by recombinant DNA technology; 
structural alterations at one or more amino acid residues modify its physical and 
pharmacologic characteristics. 
 
Secretion 
Glucose is the key regulator of insulin secretion by the pancreatic beta cell, although 
amino acids, ketones, various nutrients, gastrointestinal peptides, and 
neurotransmitters also influence insulin secretion. Glucose levels >3.9 mmol/L (70 
mg/dL) stimulate insulin synthesis, primarily by enhancing protein translation and 
processing. Glucose stimulation of insulin secretion begins with its transport into the 
beta cell by a facilitative glucose transporter (Fig. 2). Glucose phosphorylation by 
glucokinase is the rate-limiting step that controls glucose-regulated insulin secretion. 
Further metabolism of glucose-6-phosphate via glycolysis generates ATP, which 
inhibits the activity of an ATP-sensitive K+ channel. This channel consists of two 
separate proteins: one is the binding site for certain oral hypoglycemics (e.g., 
sulfonyl-ureas, meglitinides); the other is an inwardly rectifying K+ channel protein 
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(Kir6.2). Inhibition of this K+ channel induces beta cell membrane depolarization, 
which opens voltage-dependent calcium channels (leading to an influx of calcium), 
and stimulates insulin secretion. Insulin secretory profiles reveal a pulsatile pattern of 
hormone release, with small secretory bursts occurring about every 10 min, 
superimposed upon greater amplitude oscillations of about 80–150 min. Incretins are 
released from neuroendocrine cells of the gastrointestinal tract following food 
ingestion and amplify glucose stimulated insulin secretion and suppress glucagon 
secretion. Glucagon-like peptide 1 (GLP-1), the most potent incretin, is released from 
L cells in the small intestine and stimulates insulin secretion only when the blood 
glucose is above the fasting level. Incretin analogues, are used to enhance 
endogenous insulin secretion. 
 
 
Figure 2 Glucose mediated insulin secretion 
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Action  
Once insulin is secreted into the portal venous system, 50% is removed and 
degradedby the liver. Unextracted insulin enters the systemic circulation where it 
binds to receptors in target sites. Insulin binding to its receptor stimulates intrinsic 
tyrosine kinase activity, leading to receptor autophosphorylation and the recruitment 
of intracellular signaling molecules, such as insulin receptor substrates (IRS) (Fig. 
3). IRS and other adaptor proteins initiate a complex cascade of phosphorylation and 
dephosphorylation reactions, resulting in the widespread metabolic and mitogenic 
effects of insulin. As an example, activation of the phosphatidylinositol-3′-kinase (PI-
3-kinase) pathway stimulates translocation of a facilitative glucose transporter (e.g., 
GLUT4) to the cell surface, an event that is crucial for glucose uptake by skeletal 
muscle and fat. Activation of other insulin receptor signaling pathways induces 
glycogen synthesis, protein synthesis, lipogenesis, and regulation of various genes. 
 
 
Figure 3 Insulin signaling cascade 
 
Glucose homeostasis reflects a balance between hepatic glucose production and 
peripheral glucose uptake and utilization. Insulin is the most important regulator of 
this metabolic equilibrium, but neural input, metabolic signals, and other hormones 
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(e.g., glucagon) result in integrated control of glucose supply and utilization. In the 
fasting state, low insulin levels increase glucose production by promoting hepatic 
gluconeogenesis and glycogenolysis and reduce glucose uptake in insulin sensitive 
tissues (skeletal muscle and fat), thereby promoting mobilization of stored precursors 
such as amino acids and free fatty acids (lipolysis). Glucagon, secreted by 
pancreatic alpha cells when blood glucose or insulin levels are low, stimulates 
glycogenolysis and gluconeogenesis by the liver and renal medulla. Postprandially, 
the glucose load elicits a rise in insulin and fall in glucagon, leading to a reversal of 
these processes. Insulin, an anabolic hormone, promotes the storage of 
carbohydrate and fat and protein synthesis. The major portion of postprandial 
glucose is utilized by skeletal muscle, an effect of insulin-stimulated glucose uptake. 
Other tissues, most notably the brain, utilize glucose in an insulin-independent 
fashion. [12] 
1.4.SIGNS AND SYMPTOMS 
 
 
Figure 4: Signs and symptoms of diabetes 
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1.5.RISK FACTORS: [37] 
 Obesity 
 Age (onset of puberty is associated with increased insulin resistance) 
 Lack of physical activity 
 Genetic predisposition 
 Racial/ethnic background (African American, Native American, Hispanic and 
              Asian/Pacific Islander) 
 Conditions associated with insulin resistance, (e.g., polycystic ovary 
syndrome). 
 Family history of T2DM in first- or second-degree relative[13] 
 High-calorie diet 
 
1.5.1.COMPLICATIONS OF DIABETES MELLITUS [13] 
I. Acute complications 
 Hypoglycemia 
 Hyperglycemic crises 
                   a. Diabetes Ketoacidosis (DKA) 
                   b. Hyperglycemic hyperosmolar state (HHS) 
II. Chronic complications: 
 Micro vascular complications 
                 a. Diabetic retinopathy 
                 b. Diabetic nephropathy 
                 c. Diabetic neuropathy 
 Macro vascular disease 
III. Other complications and associated conditions 
 Impaired growth and development 
 Associated autoimmune conditions 
                a. Hypothyroidism 
                b. Hyperthyroidism 
                c. Celiac disease 
                d. Vitiligo 
                e. Primary adrenal insufficiency (Addison’s disease) 
 Lipodystrophy (lipoatrophy and lipohypertrophy) 
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 Necrobiosis lipoidica diabeticorum 
 Non-alcoholic fatty liver disease 
 Infections seen in patients with diabetes 
 Limited joint mobility 
 Edema 
 
Diabetes Ketoacidosis (DKA) 
DKA results from relative or absolute insulin deficiency combined with counter 
regulatory hormone excess (glucagon, catecholamine, cortisol, and growth 
hormone). Both insulin deficiency and glucagon excess, in particular, are necessary 
for DKA to develop. The decreased ratio of insulin to glucagon promotes 
gluconeogenesis, glycogenolysis, and ketone body formation in the liver, as well as 
increases in substrate delivery from fat and muscle (free fatty acids, amino acids) to 
the liver. 
           Nausea and vomiting, abdominal pain which resemble acute pancreatitis or 
ruptured viscus, Kussmaul respirations and a fruity odor on the patient's breath 
(secondary to metabolic acidosis and increased acetone) are classic signs of the 
disorder. [14] 
Hyperglycemic hyperosmolar state (HHS) 
The prototypical patient with HHS is an elderly individual with type 2 DM, with a 
several-week history of polyuria, weight loss, and diminished oral intake that 
culminates in mental confusion, lethargy, or coma. The physical examination reflects 
profound dehydration and hyper osmolality and reveals hypotension, tachycardia, 
and altered mental status. Notably absent are symptoms of nausea, vomiting, and 
abdominal pain and the Kussmaul respirations characteristic of DKA. [14] 
Chronic Complications 
The chronic complications of DM affect many organ systems and are responsible for 
the majority of morbidity and mortality associated with the disease. Chronic 
complications can be divided into vascular and nonvascular complications. 
The vascular complications of DM are further subdivided into micro vascular 
(retinopathy,neuropathy, and nephropathy) and macro vascular complications 
[coronary heart disease (CHD), peripheral arterial disease (PAD), cerebrovascular 
disease]. 
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Nonvascular complications include problems such as gastroparesis, infections, and 
skin changes. Long-standing diabetes may be associated with hearing loss. [15] 
 
Diabetic retinopathy 
DM is the leading cause of blindness. Blindness is primarily the result of progressive 
diabetic retinopathy and clinically significant macular edema. Diabetic retinopathy is 
classified into two stages: non proliferative and proliferative. 
      Non proliferative diabetic retinopathy usually appears late in the first decade or 
early in the second decade of the disease and is marked by retinal vascular micro 
aneurysms, blot hemorrhages, and cotton-wool spots. Mild non proliferative 
retinopathy progresses to more extensive disease, characterized by changes in 
venous vessel caliber, intraretinal micro vascular abnormalities, and more numerous 
microaneurysms and hemorrhages. [15] 
Necrobiosis lipoidica diabeticorum 
It is a rare disorder of DM that predominantly affects young women with type 1 DM, 
neuropathy, and retinopathy. It usually begins in the pretibial region as an 
erythematous plaque or papules that gradually enlarge, darken, and develop 
irregular margins, with atrophic centers and central ulceration. They may be painful. 
[15] 
Lipoatrophy and lipohypertrophy 
It occur at insulin injection sites but are now unusual with the use of human insulin. 
Xerosis and pruritus are common and are relieved by skin moisturizers. [15] 
 
1.6. DIAGNOSIS OF DIABETES MELLITUS 
Random plasma test 
• The simplest test and doesn’t require fasting before taking the test. 
• If 200 or more than 200 mg/dl of blood glucose it probably indicates diabetes but 
has to be reconfirmed. 
Fasting plasma glucose test: 
• There should be eight hours fasting before taking this test. Blood glucose more 
than 126 mg/dl on two or more tests conducted on different days confirms a 
diabetes diagnosis [16]. 
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 Oral glucose tolerance test 
• When random plasma glucose test is 160-200 mg/dl and the fasting plasma test is 
110-125 mg/dl, then this test is conducted [11]. 
• This blood test evaluates body’s response to glucose. This test requires fasting at 
least eight but not more than 16 hrs. 
• Fasting glucose level is determined, and then gives 75 gm of glucose, 100 gm for 
pregnant women. The blood is tested every 30 minutes to one hr for two or three 
hrs. 
• This test is normal if your glucose level at two hrs is less than 140 mg/dl. A fasting 
level of 126 mg/dl or greater and two hour glucose level of 200 mg/dl or higher 
confirms a diabetes diagnosis[16]. 
 
1.7. MANAGEMENT OF DIABETES 
 
1.7.1. Oral hypoglycemic agents: 
Oral hypoglycemic agents are used in the treatment of type 2 diabetes mellitus. The 
classification of these drugs are given below 
 
Table 1: Represents list of oral hypoglycemic agents used for the therapy of 
diabetes mellitus[17-19] 
S.
No 
Class of Drug Examples 
Mechanism of 
Action 
Adverse Effects Listed 
 
1. 
Biguanides Metformin 
Phenformin 
Supress 
Gluconeogenes
is and glucose 
output from 
liver. 
Abdominal 
pain,Anorexia,Mild 
diarrhea,Metallic 
taste,Lactic acidosis. 
2. Sulfonylureas 1st 
generation: 
      
Tolbutamide 
Chlorpropa
mide 
2nd 
generation: 
It causes 
depolarization 
of the β cell 
membrane and 
thus it enhance 
calcium influx 
which in turn 
increase the 
Hypoglycemia,Nausea, 
vomiting,headache, 
photosensitivity,rarely 
agranulocytosis may 
occur. 
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  Metformin 
   Glipizide 
   Glyclazide 
   Glimipride 
release of 
insulin from β 
cells. 
3. Meglitinide 
analogues 
Repaglinide 
Nateglinide 
 Bind to 
receptors  and 
closure of ATP 
dependent K* 
channels  
causes 
depolarization   
and promote 
insulin release. 
Dizzness,Dyspepsia 
,Arthalgia,Flu like 
symptoms may occur. 
4. Thiazolidones Pioglitazone 
Rosiglitazon
e 
 Activation of 
genes 
regulating fatty 
acid 
metabolism and 
lipogenesis 
in adipose 
tissue 
contributes to 
the insulin 
sensitizing 
action. 
Mild Anemia,Plasma 
volume 
expansion,Edema, 
weight gain, head ache. 
5. α Glucosidase 
inhibitors 
Acarbose 
Miglitol 
Inhibit α 
glucosidase 
enzyme ,there 
by it slows 
down the 
digestion of 
carbohydrates. 
Flatulence,Abdominal 
discomfort,Loose stools. 
  
1.7.2. Insulin derivatives: 
Insulin is a harmone secreted from the beta cells of pancreas which regulate the 
blood glucose level in the body.Insufficient insulin secretion leads to diabetes 
mellitus. Insulin derivatives are mainly used in the treatment of type-1 diabetes.To 
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maintain the insulin level, some synthetic insulin derivatives are synthesized and 
their classes are given below  
Table 2:  Represents list of insulin derivatives used for therapy of diabetes 
mellitus[20-22] 
S.NO TYPE OF INSULIN APPEARANCE 
ONSET 
OF 
ACTION 
DURATION 
OF 
ACTION 
1. Rapid acting: 
  Insulin lispro 
  Insulin aspart 
Clear 0.2-0.4 hr 3-5hr 
2. Short acting: 
 Clear (soluble) insulin 
Clear 0.5-1hr 6-8hr 
3. Intermediate acting: 
Insulin zinc 
suspension or lente 
Isophane insulin 
Cloudy 1-2hr 20-24hr 
4. Long acting: 
Protamine zinc insulin 
Insulin glargine 
Cloudy 2-4hr 24-36 hr 
 
1.8. INTRODUCTION OF MEDICINAL PLANTS 
Medicinal plants play an important role in the development of potent therapeutic 
agents. Today estimate that about 80 % of people in developing countries still relays 
on traditional medicine based largely on species of plants and animals for their 
primary health care. Herbal medicines are currently in demand and their popularity is 
increasing day by day. About 500 plants with medicinal use are mentioned in ancient 
literature and around 800 plants have been used in indigenous systems of medicine. 
Herbal drugs referred as plants materials or herbals, involves the use of whole 
plants or parts of plants, to treat injuries or illnesses[23]. Herbal drugs are use of 
therapeutic herbs to prevent and treat diseases and ailments or to support health 
and healing. These are drugs or preparations made from a plant or plants and used 
for any of such purposes. Herbal drugs are the oldest form of health care known to 
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mankind. World Health Organization (WHO) has distinct herbal drugs as complete, 
labelled medicinal products that have vigorous ingredients, aerial or secretive parts 
of the plant or other plant material or combinations. World Health Organization has 
set precise guidelines for the evaluation of the safety, efficacy, and quality of herbal 
medicines.  Herbal drug is a chief constituent in traditional medicine and a common 
constituent in ayurvedic, homeopathic, naturopathic and other medicine systems. 
Herbs are usually considered as safe since they belong to natural sources. The use 
of herbal drugs due to toxicity and side effects of allopathic medicines, has led to 
rapid increase in the number of herbal drug manufacturers. For the past few 
decades, herbal drugs have been more and more consumed by the people with no 
prescription. These drugs have survived real world testing and thousands of years of 
human testing. Some drugs have been discontinued due to their toxicity, while 
others have been modified or combined with additional herbs to counterbalance side 
effects[24]. 
1.8.1.Advantages of Herbal Drugs 
1.  High Low/Minimum cost 
2. Complete accessibility 
3.  Enhanced tolerance 
4.  More protection 
5. Fewer side-effects 
6. Potency and efficiency is very high 
1.8.2. Disadvantages of Herbal Drugs 
1. Not able to cure rapid sickness and accidents 
2. Risk with self-dosing 
3. Complexity in standardizations 
1.8.3. Importance of plants as a source of new drugs[25] 
The development of traditional medicinal systems incorporating plants as means of 
therapy can be traced back to the Middle Paleolithic age some 60,000 years ago as 
found from fossil Studies. In recent times, developed countries are turning to the use 
of traditional medicinal systems that involve the use of herbal drugs and remedies 
and according to the World Health Organization (WHO), almost 65% of the world’s 
population has incorporated the value of plants as a methodology of medicinal 
agents into their primary modality of health care. It is often noted that 25% of all 
drugs prescribed today come from plants. 
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1.8.4. Plants used for the treatment of diabetes[26-32] 
Table:3 list of available plants used for  the therapy of diabetes mellitus 
S. 
NO 
BOTANICAL 
NAME 
FAMILY 
PARTS 
USED 
MAIN ACTIVE 
CONSTITUENTS 
1. Allium sativum Alliaceae Bulbs Allyl propyl disulphide, 
allicin 
2. Annona 
squamosa 
Annonaceae Fruits Liriodenine, moupinamide 
3. Areca catechu Arecaceae Seed Arecaine and arecoline 
4. Artemisia 
pallens 
Asteraceae Leaves 
and flowers 
Germacranolide 
5. Azadirachta 
indica 
Meliaceae Leaves, 
flowers & 
Seed 
Azadirachtin and nimbin 
6. Bauhinia 
forficate 
Leguminosae Leaf Astragalin, kaempferitrin 
7. Beta vulgaris Amaranthaceae Root Phenolics, betacyanins 
8. Boerhavia 
diffusa 
Nyctaginaceae Whole 
plant 
Punarnavine and ursolic 
acid 
9. Camellia 
sinensis 
Theaceae Leaves caffeine and catechins 
10. Capparis 
deciduas 
Capparidaceae Fruit Spermidine 
Isocodonocarpine 
11. Cinnamomum 
Zeylanicum 
Lauraceae Bark Cinnamaldehyde, eugenol 
12. Combretum 
Micranthum 
Combretaceae Leaves Polyphenols 
13. Elephantopus 
scaber 
Asteraceae Whole 
plant 
Terpenoid and 2,6,23 - 
Trienolide 
14. Ficus 
bengalensis 
Linn 
Moraceae Bark Leucodelphinidin and 
Leucopelargonin 
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15. Gymnema 
sylvestre 
Asclepiadaceae Leaf Dihydroxy gymnemic 
triacetate 
16. Gynandropsis 
Gynandra 
Capparidaceae Root N,N-diethyltoluamide 
17. Lantana 
camara 
Verbenaceae Leaves Lantanoside, lantanone 
18. Liriope spicata Liliaceae Root Beta-sitosterol, 
stigmasterol 
19. Momordica 
charantia 
Cucurbitaceae Leaves Charantin, sterol 
20. Ocimum 
sanctum 
Labiatae whole plant Eugenol 
21. Panax 
quinquefolius 
Araliaceae Root Ginsenosides, 
protopanaxadiol 
22. Parinari excels Chrysobalanaceae Bark Myricetin, quercertin 
23. Phyllanthus 
amarus 
Phyllanthaceae whole plant Phyllanthin 
24. Prunus 
amygdalus 
Rosaceae Seeds Amygdalin 
25. Pterocarpus 
marsupium 
Leguminosae Whole 
plant 
Kenotannic acid, 
pyrocatechin 
26. Punica 
granatum 
Lythraceae Fruit Punicalagin, punicalin 
27. Ricinus 
communis 
Euphorbiaceae Root Ricinolic acid 
28. Salacia 
oblonga wall 
Celastraceae Root bark Salacinol 
29. Sarcopoterium 
Spinosum 
Rosaceae Root Catechin and epicatechin 
30. Smallanthus 
Sonchifolius 
Asteraceae Leaves Sonchifolin, uvedalin, 
enhydrin, fluctuanin 
31. Swertia 
punicea 
Gentianaceae Whole 
plant 
Methyl swertianin and 
Bellidifolin 
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32. Tinospora 
cordifolia 
Menispermaceae Root Tinosporone, tinosporic 
acid 
33. Trigonella 
foenum 
Graecum 
Fabaceae Leaves 
and seeds 
4-hydroxy isoleucine 
34. Vernonia 
anthelmintica 
Asteraceae Seed Epoxy acid or vernolic 
acid 
35. Withania 
somnifera 
Solanaceae Whole 
plant 
Somniferine,withananine 
and 
Cuscohygrine 
36. Aloe 
barbadenis 
Liliaceae Whole 
plant 
Pseudoprototinosaponin A 
III and Prototinosaponins 
AIII 
37. Anemarrhena 
asphodeloides 
Liliaceae Leaves Magniferin, Magniferin-7-
0-β dglucoside 
38. Bauhinia 
variegeta 
Casealpiniaceae Aerial parts Roseoside 
39. Citrullus 
colocynthis 
Cucurbitaceae Leaves Beta pyrazol- 1-yalalanine 
40. Ephedra 
distachya 
Ephedraceae Whole 
plant 
L-ephedrine 
41. Eriobotrya 
japonica 
Rosaceae Aerial parts Cinchonain ib 
42. Eugenia 
jambolona 
Mytraceae Fruit 4-hydroxy benzoic acid 
43. Accacia 
Arabica 
Fabaceae Seed, 
Bark 
Polyphenol,Tannins 
44. Cassia 
auriculata 
Fabaceae Flower Sterol,terpenoid,flavanoid, 
Tannins 
45. Glycine max Fabaceae Seed 3-O-methyl-D-chiro-
inositol 
46. Tamarindus 
indica 
Fabaceae Seed, Fruit Flavonoid, Polysaccharide 
DEPARTMENT OF PHARMACOLOGY,AKCP Page 18 
 
47. Xanthocercis 
Zambesiaca 
Fabaceae Leaf Fagomine, 4-O-beta-
Dglucopyranosylfagomine, 
Castanospermine 
48. Butea 
monosperma 
Fabaceae Fruit Butein, Palasonin, 
Stigmasterol-3 β- 
D-glucopyranoside 
49. Aegle 
marmelos 
Rutaceae Leaf, 
Seed, 
Fruit 
Aegeline 2, Coumarin, 
Flavonoid, 
Alkaloid 
50. Citrus reticulate Rutaceae Fruit Essential oil 
 
1.8.5.Marketed Herbal Formulations for the Therapy of Diabetes[33,34] 
Table 4: some herbal formulations for the management of diabetes 
S.NO FORMULATION NAME         INGREDIENTS 
1. Adcaps  
 
Haldi, Jambuphal, Amla, Mamajov, Neem, 
Karela, Vijaysar, Tejba, Gulvel Sudha, 
Guggl, Trivang Nag Suvarnamakshik 
bhasm, Shilajeet, Ashok and Madhunasni  
2. BZR-34  
 
Bereris aristata, Ptercarpus marsupium, 
Gymnema sylvestre, Rubia cordifolia, 
Trigonella feounum, Berberis aristata, and 
Tinopora cordifolia  
3. Asanand  
 
Arjuna, Ganasar, Karanja, Kanth, Lodhra, 
Palash and Shirish  
4. Diasulin  
  
 
 
Cassia auriculata, Coccinia indica, 
Momordica charantia, Syzygium cumini, 
Emblica officinalis, Trigonella foenum 
graecum, Curcuma longa, Gymnema 
sylvestre, Tinospora cordifolia, and 
Scoparia dulcis  
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5. Diabecure  
 
 
Berberis vulgaris, Erytherea centaurium, 
Juglans regia, millefolium and taraxacum  
 
6. Panvli  
 
Amla, Gudmar, Gul vel, Haldi, Kanth, 
Karvas, Panvelley and Yashti,  
 
 
1.9. PHYTOSOMES 
From the last century, there are valuable criteria has been kept it up and centred on 
the event of Novel drug delivery system (NDDS) for herbal medicines. Researchers 
have the reputable the potential edges of novel drug delivery in providing immense 
enhancements to deliver the drug and drug targeting. Improving delivery technique, 
minimize toxicity, improve efficaciousness offers an excellent potential edges to 
patients and expose new markets for Pharmaceutical and drug corporations.  
Preparations of plants or parts of them were widely used in popular medicine since 
ancient times and till today the use of phytomedicines is widespread in most of the 
world’s population. The term ‘Phyto’ means plant while ‘Some’ means cell-like. 
Phytosome is vesicular drug delivery system in which phytoconstituents of herb 
extract surround and bound by lipid. The Phytosomes process produces a little cell 
because of that the valuable components of the herbal extract are protected from 
destruction by digestive secretions and gut bacteria. Phytosomes are better able to 
transition from a hydrophilic environment into the lipid-friendly environment of the 
enterocyte cell membrane and from there into the cell finally reaching the blood. 
Phytosome is a newly introduced patented technology developed to incorporate the 
standardized plant extracts or water-soluble phytoconstituents into phospholipids to 
produce lipid compatible molecular complexes, which improves their absorption and 
bioavailability. Phytosomes are more bioavailable as compared to herbal extract 
owing to their enhanced capacity to cross the lipid rich biomembranes and finally 
reaching the blood. The phytosome process has been applied to many popular 
herbal extracts including Ginkgo biloba, grape seed, hawthorn, olive fruits and 
leaves, milk thistle, green tea, ginseng, kushenin, marsupsin and curcumin. The 
flavonoid and terpenoid components of these herbal extracts are able to directly bind 
to phosphatidylcholine. Increased bioavailability of the phytosomes over the simpler, 
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non-complexed plant extract has been demonstrated by pharmacokinetics and 
activity studies, conducted in animals as well as human beings[35]. 
 
1.9.1. Advantages of Phytosomes 
 They permeate the non-lipophilic botanical extract to allow better absorption 
from the intestinal lumen, which is otherwise not possible. 
 The formulation of phytosome is safe and the components have all been 
approved for pharmaceutical and cosmetic use. 
 They have been used to deliver liver protecting flavonoids because they can 
be made easily bioavailable by phytosomes. In addition to this, 
Phosphatidylcholine is also hepatoprotective and so provides a synergistic 
effect for liver protection. 
 There is no problem with drug entrapment during formulation preparation. 
Also, the entrapment efficiency is high and moreover predetermined; because 
the drug itself forms vesicles after conjugation with lipid[36]. 
 Phosphatidylcholine used in formulating phytosome process besides acting as 
a carrier also nourishes the skin as it is an essential part of a cell membrane. 
 Phytosomes are also superior to liposomes in skin care products. 
 Phytosomes proves to be of significantly greater clinical benefit. 
 Their low solubility in aqueous media allows the formation of stable emulsions 
or creams[37]. 
 Facilitates the liver targeting by increasing the solubility in bile salt. 
 Phytosomes are better able to transition from a hydrophilic environment into 
the lipid‐friendly environment of the enterocyte cell membrane and from there 
into the cell, and thus can be used for systemic targeting. 
  Phytosome are widely used in cosmetics due to their more skin penetration 
and have a high lipid profile[38]. 
 
1.9.2. Properties of Phytosomes 
Following are some of the important properties of phytosomes: 
1.9.2.a. Physico-chemical properties 
a) Phytosome are prepared by reaction of stoichiometric amount of phospholipid 
with the standardized plant extracts as substrate. The spectroscopic data reveals 
that the phospholipid substrate interaction is due to the formation of hydrogen bond 
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between the polar head (i.e. phosphate and ammonium group) and the polar 
functionalities of the substrate.  
b) The size of Phytosome varies from 50 nm to a few hundred μm. 
c) Phytosome when treated with water assumes a micellar shape resembling 
liposome and photon correlation spectroscopy (PCS) reveals this liposomal 
structures acquired by phytosome. 
d) The H1NMR and C13 NMR data deduced that the fatty chain gives unchanged 
signals both in free phospholipid and in the complex, which indicates that long 
aliphatic chains are wrapped around the active principle producing lipophilic 
envelope. 
e) The complexes are often freely soluble in aprotic solvents, moderately soluble in 
fats, insoluble in water and relatively unstable in alcohol. But the phytosomes of 
certain lipophilic phytoconstituents like curcumin has shown increase in water 
solubility upon complexation with phospholipid. 
1.9.2.b. Biological properties 
Phytosome are novel complexes which are better absorbed and utilized; hence they 
produce more bioavailability and better result than the conventional herbal extract or 
non-complex extracts, which has been demonstrated by pharmacokinetic studies or 
by pharmacodynamic tests in experimental animals and in human subjects[39]. 
 
1.9.3. Bioavailability of Phytosomes 
It is evident from many research studies that phytosomes have an improved 
absorption and bioavailability when compared to the conventional means. Most of 
the research studies are focused on Silybum marianum (milk thistle), the fruit of 
which contains a water-soluble phytoconstituent (flavonoids) which is known to have 
a hepatoprotective effect. But these flavonoids are poorly absorbed. The chief and 
most potent constituent of milk thistle is Silybin.  
A brief summary of some of the research studies is given as: 
 According to Crema et al., 1990, when single oral doses of Silybin directly 
bound to phosphatidylcholine (Silybin phytosome) are fed, its absorption was 
approximately seven times more than the absorption from regular milk thistle 
extract containing 70-80% silymarin content). 
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 A research study was conducted by (Yanyu etal., 2006) in which he prepared 
silymarin phytosome and has shown its pharmacokinetics in rats. The 
phytosome was administrated to rats orally. The results showed that the 
bioavailability and biological effects of Silybin was increased remarkably. 
 some of the studies have reported the better results produced by consuming 
ginkgo phytosome than the conventional gingko extract. A bioavailability 
study was conducted on healthy human volunteers in which it was found that 
the levels of flavonoids and terpenes (GBE constituents) peaked after 3 hours 
and persisted longer last for 5 hours. One study shows that some patients 
suffering from Reynaud’s disease and intermittent circulation were fed with 
ginkgo phytosome which was shown to produce a 30-60% greater 
improvement compared to regular standardized GBE (Ginkgo biloba 
extract)[32]. 
                      
                 Figure 5   Phytosome 
1.9.4. Applications of Phytosomes[39-44] 
To examine the various advantages of phytosomes, especially their ability to 
enhance the bioavailability of polar phytoconstituents, various therapeutic 
applications of phytosomes have been explored. The details of the type of 
phytosomes, active constituents, the daily dose and specific indications are given in 
(Table 1). 
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Table 5: Therapeutic applications of different Phytosomes with their dose 
S. 
No. 
Phytosomes 
Phytoconstituent 
complexed with 
PC 
Daily 
dose 
Indications 
1 Leucoselect® 
phytosome 
Procyanidolic 
oligomers (PCOs) 
from grape seeds 
50-100 
mg 
Systemic 
antioxidant, specific. 
Best choice for 
most people under 
age of fifty. Also 
specific for the 
eyes, lungs, 
diabetes, varicose 
veins, and 
protection against 
heart disease. 
2 Greenselect® 
phytosome 
Epigallocatechin 3-
O-gallate from 
camelia sinensis 
(Green tea) 
50-100 
mg 
Systemic 
antioxidant. Best 
choice for protection 
against cancer and 
damage to 
cholesterol 
3 Ginkgoselect® 
phytosome 
24% ginkgo 
flavono glycosides 
from Ginkgo biloba 
120 mg Best choice for 
most people over 
the age of 50. 
Protects brain and 
vascular lining [34] 
4 Silybin 
phytosome 
Silybin from 
silymarin (milk 
thistle) 
120 mg Best choice if the 
liver or skin needs 
additional 
antioxidant 
protection 
5 Siliphos TM milk 
thistle 
phytosome 
Silybin from 
silymarin 
150 mg Good choice for 
liver or skin 
support[35] 
6 Hawthorn 
phytosome 
Flavonoids 100 mg Best choice in heart 
disease 
7 Panax ginseng 
phytosome 
37.5% 
ginsenosides from 
roots of Panax 
ginseng 
150mg As a Food Product 
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8 Glycyrrhiza 
phytosome 
18-beta 
glycyrrhetinic acid 
50-100mg Anti-inflammatory 
Activity[36] 
9 Mirtoselect® 
Phytosome 
Anthocyanosides 
froman extract of 
Bilberry 
150mg These improve 
capillary tone, 
reduce abnormal 
blood vessel 
permeability & are 
potent antioxidants. 
They hold great 
potential for the 
management of 
retinal blood vessel 
problems and 
venous 
insufficiency. 
10 Sabalselect® 
Phytosome 
An extract of 
sawpalmet 
toberries 
through 
supercriticalCO2 
(carbondioxide) 
extraction 
100mg It delivers fatty 
acids, alcohols and 
sterols that benefit 
prostate health. 
Also beneficial for 
non-cancerous 
prostate 
enlargement 
11 PolinaceaTM 
Phytosome 
Echinacosides and 
a unique high-
molecular weight 
Polysaccharide 
from Echinacea 
Angustifolia 
120mg It enhances immune 
function in response 
to a toxic challenge 
12 OleaselectTM 
Phytosome 
Polyphenols from 
olive oil 
100mg As potent 
antioxidants, inhibit 
harmful oxidation of 
LDL cholesterol, 
and also have anti-
inflammatory 
activity. 
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CHAPTER-II 
PLANT PROFILE 
 
 
 
                                  Figure 6:  Trigonella foenum graceum 
 
2.1. TAXONOMY OF TRIGONELLA FOENUM GRACEUM[44] 
The botanical classification of Trigonella foenum graceum is as following, 
Kingdom:            Plantae 
Super division:  Angiosperms 
Division:   Eudicots 
Class:             Rosids 
Order:   Fabales 
Family:            Fabaceae 
Subfamily:   Faboideae 
Tribe:    Trifolieae 
Genus:   Trigonella 
Species:             Foenum  
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2.2. VERNACULAR NAMES OF TRIGONELLA FOENUM GRACEUM[45] 
Botanical Name Trigonella Foenum-graecum 
English Name 
Fenugreek, Sickle Fruit fenugreek, Greek 
hay 
Hindi Name Methi 
Sanskrit Name Methika 
Tamil Name Vendhayam 
Tegulu Name Menthulu 
 
2.3. ETYMOLOGY:  
          Fenugreek is derived from foenum-graceum which in turn gives the scientific 
name of this plant. Foenum- graceum means “green hay”. It was named line this 
because of the strongest smell of this plant, reminiscent of the hay, as extensively 
cultivated in the mediterranean region. 
2.4. ORIGIN: 
        Western Mediterranean native plant and spread throughout the Mediterranean 
region since ancient times. 
2.5. HABITAT: 
        Road sides, uncultivated land, dry grassland, waste land and harvesting lands 
(grain fields). 
2.6. GEOGRAPHICAL DISTRIBUTION: 
                 Middle east, Persia, India, China, Central and Southern Europe, 
Mediterranean region ,North Africa, United states. 
2.7. MORPHOLOGY[46]: 
   Fenugreek(Trigonella foenum graceum) is an annual  herbaceous plant of the 
family Leguminosae family ,measuring between 20 and 50 cm upto 100cm high. 
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2.7.1. Stem:  Erect,branched,grooved and with little pubescence. 
2.7.2. Leaves: The leaves are compound, petiolated, consists of three oblong 
gleaflets, attenuated towards the base and with toothed margins. Size 20-50 x 8 -17 
mm. 
2.7.3. Flowers: The flowers are white or yellow ,grow from the laef axils  and are 
arranged singly or in little groups of two. Corolla 12-18 mm. It flowers in April and 
May. 
2.7.4. Fruits:  The fruits are  pods or legumes  narrow and oblong, resembling a 
sickle.Pod 80-150 x 2-4 mm with elongated beak at the end. The fruits ripen in 
summer and harvested in autumn.  
2.7.5. Seeds:  Inside of them , there are between 10-20  tiny seeds. Size 3mm. The 
seeds are approximately yellow, quandragular and with a groove in the central part. 
   The whole plant gives  off an unpleasant odour, reminiscent of hay.  
2.8. USED PARTS: 
2.8.1. Seeds: Smal grains are used  as a condiment or spice , and in herbal 
medicines for its medicinal properties. These seeds have an unpleasant taste , So 
that they are used in small quantities or mixed with other aromatics ,such as curry 
mix. 
2.8.2. Leaves: The leaves of this plant are edible. In some oriental restaurants ,they 
are consumed in the traditional alu methi,made with steamed  fenugreek leaves. This 
delicacy ,little known in the west, is a vegetable particularly rich in choline and 
betacarotene. 
2.8.3. Green pasture: Fenugreek is also a fodder plant. Like other pasture legumes 
, fenugreek  increases the production of milk and meat of the cattle. It is a major 
source of digestable protein of good quality. 
2.9. CHEMICAL CONSTITUENTS[46]: 
 Carbohydrates: Fructose,sucrose,xylose,arabinose,raffinose,stachyose. 
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 Fibre: It has a high percentage of soluble fibre such as mucilage and 
galactomannans. This type of fibre ,which accounts for 25-45% of whole 
grain, provides emollient effect,protects the digestive mucosa and it is a 
natural intestinal regulator. 
 Protein: Fenugreek is high in easily assimilated protein and rich in 
phosphorus, so it has been indicated as plant tonic .It contains mucins, which 
are a type of protein  with gelling power. 
 Amino acids: Cysteine, proline, tryptophan, Phenylalanine and lysine. It also 
contains 4-hydroxyisoleucine acid with cholesterol lowering  properties. 
 Fat: It contains lecithin . Among its fatty acid , predominates linoleic acid. 
 Minerals: Calcium, phosphorus, Potassium, selenium, Chromium, copper, 
sodium. 
 It contains Trigonelline (Nicotinic acid derivative) and trigonellosides.This 
substance has hypoglycemic action. 
 Aromas: The aroma of the fenugreek is also due to a galactone called 
sotolone. 
 Alkaloids: Carpaine, gentianine. 
2.10.TRADITIONAL USES[47]: 
 Fenugreek is an esteeemed medicine in North Africa, the Middle East, and 
India, being used for a wide variety of conditions. The nourishing seeds are 
given during convalescence and to encourage weight gain, especially in 
anorexia. 
 Helpful in lowering fever, it is compared to quinine by some authorities. 
 The seeds’ soothing effect makes them of value in treating gastritis and 
gastric ulcers. 
 They are used to induce childbirth and to increase breast-milk production. 
 They are also used to lower blood sugar and blood cholesterol levels. 
 Externally, the seeds are applied as a paste to treat abscesses, boils, ulcers, 
and burns, or used as a douche for excessive vaginal discharge. 
 The seeds freshen bad breath and help restore a dulled sense of taste. 
 The oil in the seeds is used as a skin softener and emollient. 
 In China, the seeds are used as a pessary to treat cervical cancer. 
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 In the Middle East and the Balkans, the aerial parts are a folk remedy for 
abdominal cramps associated with both menstrual pain and diarrhea or 
gastroenteritis. They are also used to ease labour pains. 
 Herbalists in Asia and the Mediterranean often recommend fenugreek to 
stimulate contractions in delayed or sluggish labour 
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                                             CHAPTER III 
REVIEW OF LITERATURE 
1.  Aili Aierken et al., (2017)[48] reported that Hawthorn is a popular herb in many 
different traditional medicine systems, including traditional Chinese medicine, where 
it has long been used for the treatment of hyperglycemia. However, most of its varied 
biological activities remain unexplored. This study investigated the hypoglycemic 
effect of hawthorn extracts in type II diabetic (T2DM) rat model. A total of 54 rats 
were randomly divided into six groups: normal control group; type II diabetic model 
group (T2DM; these rats were induced by high‐fat diet and streptozotocin); high, 
middle and low concentrations of hawthorn treatment (HTH, HTM and HTL T2DM rats 
were given hawthorn extract at a dose of 50, 100 and 200 mg kg−1 body weight, 
respectively); and positive control group (orlistat 40 mg kg−1body weight). 
2. Kotha et al., (2017)[49] investigated that the anti-diabetic activity of leaves 
of Anisomeles malabarica following bioactivity guided fractionation. The different 
solvent (hexane, ethyl acetate, methanol and water) extracts of A. malabarica leaves 
were used in acute treatment studies to evaluate and identify the active fraction. The 
ethyl acetate extract was subjected to further fractionation using silica gel column 
chromatography and the compounds were identified by LC-SRM/MS and GC-MS. 
Additional chronic treatment studies were carried out using this active fraction 
(AMAF) for 30 days in experimental diabetic rats. Fasting blood glucose (FBG), 
glycosylated hemoglobin (HbA1c), plasma insulin levels and glucose tolerance were 
measured along with insulin resistance/sensitivity indicators (HOMA-IR, HOMA-β 
and QUICKI) to assess the beneficial effects of A. malabarica in the management of 
diabetes mellitus. Among the different solvent extracts tested, ethyl acetate extract 
showed maximum (66%) anti-hyperglycemic activity. The hexane and ethyl acetate 
(1: 1) fraction that has maximum anti-diabetic activity was identified as active fraction 
of A. malabarica (AMAF). The FBG, HbA1c, plasma insulin levels and insulin 
sensitivity/resistance indicators such as glucose tolerance, HOMA-IR, HOMA-β and 
QUICKI were significantly improved to near normal in diabetic rats treated with 
AMAF. Further, we identified key flavonoids and fatty acids as the anti-diabetic active 
principles from the AMAF of A. malabaricaleaves 
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3. Lavakumar et al., (2016)[50] reported that present investigation was considered in 
arraying of anti-diabetic and anti-oxidant activity from dietary flavanoid loaded 
fraction of Acanthophora spicifera (Family: Rhodomelaceae) on streptozotocin (STZ) 
induced oxidative stress rats. The testings were acted upon male rats, which were 
alienated into five groups: control group, diabetic group (single dose of 65mg/kg, 
STZ i.p.) diabetic with insulin (6IU), and diabetic with flavonoid rich fraction groups 
(FRF) at 50 and 100mg/kg body weight, given orally for 21 days. The anti-oxidant 
consequences of FRF on STZ-induced diabetic rats were determined by the 
estimations of the oxidative stress marker like malnonyldialdehyde and antioxidant 
enzymes such as superoxide dismutase, catalase and glutathione in tissue 
homogenates of heart, liver and kidney. FRF treatment of diabetic rats significantly 
(P<0.05) diminishes the blood glucose altitudes to normal in contrast with diabetic 
rats. However, FRF administration, significantly decreased the malonyldialdehyde 
(MDA) and increased the activities of superoxide dismutase (SOD), catalase(CAT) 
and glutathione levels (GSH) in diabetic rats. 
4. Ramadan et al., (2017)[51] reported  that Diabetes is a major public health 
concern. In spite of continuous new drug development to treat diabetes, herbal 
remedies remain a potential adjunct therapy to maintain better glycemic control while 
also imparting few side-effects. Portulaca oleracea has been traditionally used to 
manage several diseases due to the anti-oxidant and anti-atherogenic effects it 
imparts. To better understand the mechanisms associated with potential protective 
effect of P. oleracea extract against diabetes, alloxan-induced diabetic rats were 
used in this study. Forty Wistar rats (male, 7–8-wk-old, 140–160 g) were divided into 
four groups (n = 10/group): Group I (control), Group II (P. oleracea-treated; gavaged 
with P. oleracea extract daily [at 250 mg/kg] for 4 weeks), Group III (diabetic control; 
daily IP injection of alloxan [at 75 mg/kg] for 5 days) and Group IV (P. oleracea-pre-
treated diabetic; gavaged with P. oleracea extract daily [at 250 mg/kg] for 4 weeks 
and then daily IP injection of alloxan [at 75 mg/kg] for 5 days). Body weight, food 
consumption, blood (serum) levels of glucose, C peptide, Hb A1C, insulin, tumor 
necrosis factor (TNF)-α and interleukin (IL)-6 were determined for all group 
5. Dhase et al., (2015)[52] have reported Preparation and Evaluation of Phytosomes 
containing methanolic extract of Leaves of Aegle Marmelos (Bael). Lipid compatible 
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molecular complex of extract is called as phytosomes. Phytosome technology is 
applied to water soluble phytoconstituents tannins, phenols, terpenoids,etc. 
Phytosomes was prepared by solvent evaporation method and further evaluated it 
for particle size, digital microscopy, SEM, TEM, FTIR, DSC, XRD analysis. From 
above studies they have concluded that phytosomes has better physical 
characteristics as compared to that of methanolic extract of leaves of A.marmelos. 
Phytosomes has nearly same anti-oxidant, anti proliferative and anticancer activity 
as that of methanolic extract of leaves of A.marmelos. 
6. Pedro H. Miranda-Osorio et al., (2016)[53] reported the effect of C. papaya L. leaf 
extract (CPLE)on pancreatic islets in streptozotocin (STZ)-induced diabetic rats, as 
well as on cultured normalpancreatic cells with STZ in the medium. CPLE (3–125 
mg/Kg) was administered orally for 20 days,while a group of diabetic rats received 5 
IU/Kg/day of insulin. At the end of the treatment the rats were sacrificed. Blood was 
obtained to assess glucose and insulin levels. The pancreas was dissected to 
evaluate _ cells by immunohistochemistry. In addition, normal pancreatic cells were 
cultured in a medium that included CPLE (3–12 mg). One half of the cultured cells 
received simultaneously CPLE and STZ (6 mg), while the other half received CPLE 
and five days later the STZ. After three days of incubation, insulin was assayed in 
the incubation medium. The CPLE administered to diabetic rats improved the fasting 
glycemia and preserved the number and structure of pancreatic islets. 
However,when CPLE was added to pancreatic cells in culture along with STZ, the 
insulin concentration was higher in comparison with the cells that only received STZ.  
7. Moses soloman agawaya et al., (2016)[54] evaluated the effect of aqueous root 
bark extract of Zanthoxylum chalybeum on oral glucose tolerance and pancreas 
histopathology in alloxanized rats.Diabetes was induced in rats by administration of 
alloxan monohydrate. Root extract of Z. chalybeum was administered to rats at 200 
and 400 mg/kg BW daily for 28 days. Blood glucose was measured by glucometer 
and pancreatic histopathology evaluated microscopically. Initial increase was 
observed in blood glucose of the rats after oral administration of glucose from time 
zero. Two hours after treatment with Z. chalybeum, a significant reduction in blood 
glucose was observed within treatment groups (p<0.05) compared to 0.5 hr and 1 hr. 
There was no significant difference between treatment group receiving 400mg/Kg 
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BW extract and the normal groups (p=0.27), implying that the former group 
recovered and were able to regulate their blood sugar, possibly via uptake of glucose 
into cells. The reversal in pancreatic histopathology further supports the protective 
effect of Z. chalybeum extract towards diabetic damage. Conclusion. Extract of Z. 
chalybeum is effective in controlling blood glucose in diabetes and protecting 
pancreatic tissues from diabetic damage. 
8. Maisa MA Al-Qudah et al., (2016)[55] reported the biochemical and histological 
changes in the pancreas of rats exposed to aqueous extract of ginger. Twenty adult 
female albino rats were divided into four groups of five each: Group I, the control 
group. Group II: Untreated diabetic rats (injected with 65mg/kg Body Weight (BW) of 
alloxan intraperitoneally); received distilled water. Group III: Diabetic rats; received 
500 mg/kg BW/day of the ginger extract. Group IV: Diabetic rats; received 1000 
mg/kg BW/day of the ginger extract. The treatment continued for 21 days, then rats 
were anesthetized, and their pancreases were extirpated to be processed for light 
microscopic examinations. The alloxan induced rats exhibited hyperglycemia 
accompanied with increases in glucose, Total Cholesterol (TC), Low Density 
Lipoprotein Cholesterol (LDL-C) and Triglycerides (TG) levels. On the other hand, 
there were reductions in insulin and High Density Lipoprotein Cholesterol (HDL-C) 
levels. Ginger was effective in lowering serum glucose and returned the other earlier 
mentioned blood assays levels in the ginger treated diabetic rats to almost normal 
value.. 
9. Manjeshwar Shrinath Baliga et al., (2017)[56] reported Diabetes mellitus, a 
metabolic disorder of the endocrine system is one of the World’s oldest diseases 
known to man. Since time immemorial plants have been used as anti-diabetic agents 
in the various traditional systems of medicine. Trigonella foenum-graecum commonly 
known as fenugreek in English and methi in various Indian languages is one such 
plant and has been an integral part in the treatment of diabetes in the Indian 
traditional system of medicine the Ayurveda. The seeds and leaves have been 
documented to be useful in reducing hyperglycemia and its complications. This 
review collates the traditional uses and validated anti-diabetic effects of the 
fenugreek leaves and on the mechanisms contributing to the therapeutic effects. 
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10. Singh et al., (2015)[57] reported that Lawsonia inermis L. (Lawsone) has low 
bioavailability because it is less soluble in water and it is rapidly eliminated from 
body.  The aim of this study was to prepare the phytosome of lawsone and evaluate 
it. Different phytosome complexes of lawsone containing molar ratio of 1:1, 1:2, 2:1 
and 2:2 of lawsone and soya lecithin were prepared by the anti-solvent precipitation 
technique. The phytosome was characterized by SEM, DSC and FT-IR. Antifungal 
activity of phytosome of lawsone was evaluated on Candida albicans (NCIM 3471) 
fungi by using ketoconazole as standard drug. SEM and DSC data showed that 
phytosome complex of lawsone has irregular size vesicles consisting of soya lecithin 
and lawsone was found to be intercalated in the lipid layer. Antifungal activity of 
phytosome complex (1:1) showed the biggest zone of inhibition as compared to 
phytosome complex (1:2), plant drug and standard drug ketoconazole after 3 days. 
The anti-inflammatory activity of gel of phytosome of lawsone showed significant 
anti-inflammatory activity as compared to plant drug gel at 4 h (P < 0.001). 
11. Hamidpour et al., (2016)[58] reported that this minireview article analyzes the 
medicinal and remedial properties of Trigonella foenum graceful L. (fenugreek) as an 
alternative remedy for diabetes mellitus.  To understand fenugreek and the 
components of fenugreek seed extract (dysgenic, ethanol extract, hydro alcoholic 
extract, aqueous extract and methanol extract, IND01) as a remedial agent for 
diabetes mellitus in various in vitro and in vivo studies.  
12. Kailash et al.,(2017)[59] carried out an anti-diabetic effect to compare anti-
diabetic effect between the different aqueous extracts of green leafy plants locally 
available in North Karnataka region of India on alloxan induced diabetic male albino 
rats.: The preparation of aqueous extracts, preliminary phytochemical analysis and 
toxicity screening test of 3 aqueous extracts was done by using standard protocol. 
To study anti-diabetic activity experimental rats were divided into five groups viz. 
Group I (Control), Group II (Diabetic, Alloxan monohydrate, 15mg/100g bwt, i.p.), 
Group III (Diabetic with Trigonella foenum graecum), Group IV (Diabetic with 
Hibiscus cannabinus Linn) and Group V (Diabetic with Cicer arietinum). All above 
extracts were supplemented with same dose i.e. 12.5mg/100g bwt, orally. The blood 
glucose levels were evaluated in all the above experimental groups after acute 
(OGTT) and sub chronic (2 weeks) supplementation. Results: Our results depicts 
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statistically significant decreased blood glucose level in Group III rats after both 
acute and sub chronic supplementation whereas in Group IV rats only after sub 
chronic supplementation when compared with Group II rats. But, Group V rats not 
showed any significant change in both acute as well as sub chronic exposure when 
compared with Group II rats. Trigonella foenum graecum and Hibiscus cannabinus 
Linn. leaves may be used as a dietary supplement in diabetic patients. 
13.  Sapneh Sharma et al., (2015)[60] reported that this study was undertaken to 
evaluate the antihyperglycemic and antioxidative potential of seed powder 
of Trigonella foenum-graecum L in alloxan (55 mg/kg) induced diabetic rats. The 
results obtained showed that extensive oxidative stress is generated in tissues of 
diabetic rats as evidenced by increased production of hydrogen peroxide, increased 
accumulation of malondialdehyde (MDA) and 4-hydroxynonanal (4HNE) and 
decreased activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), 
and catalase (CAT) in tissues of diabetic rats. It was observed that the transcription 
of genes of SOD, GPx, and CAT was also significantly decreased when compared 
with control. Treatment of Trigonella for 15 days to diabetic rats showed 
hypoglycemic effect and improved the altered levels of H2O2, MDA, and 4HNE, the 
activities of SOD, GPx, and CAT as well as transcription of these genes in the liver 
and the brain of diabetic rats. 
14 Piero NM, et al., (2015)[61] reported this study was to determine in vivo 
hypoglycemic activity and safety of aqueous leaf extracts of C. pareira in white male 
albino rats. The extracts were screened for their hypoglycemic activity in alloxan 
induced diabetic rats using the oral and intraperitoneal routes. The safety of these 
extracts was studied in rats orally or intraperitoneally administered with 1 g/kg body 
weight daily for 28 days by recording the changes in body and organ weight, 
hematological and biochemical parameters and histology. Mineral composition of the 
extracts were estimated using total reflection X-ray fluorescence system (TRXF) 
while the types and quantities of phytochemicals present were assessed using 
standard procedures. Aqueous extracts orally and intraperitoneally administered at 
50 mg/kg, 100 mg/kg and 150 mg/kg body weight demonstrated hypoglycemic 
activity with the intraperitoneal route being more effective than the oral route. Oral 
and intraperitoneal dose of 1 g/kg body weight of the leaf extracts significantly 
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reduced the body weight gain. The same intraperitoneal dose increased the liver and 
spleen, and decreased the testis weight; and reduced the hemoglobin levels, packed 
cell volume and increased the platelet count; increased the activity of aspartate 
aminotransferase, and lactate dehydrogenase, and decreased the activity of alkaline 
phosphatase, γ-glutamyltransferase, and creatine kinase and histologically slightly 
injured the liver and spleen and orally increased the activity of alanine 
aminotransferase, lactate dehydrogenase, and creatine kinase, and decreased the 
activity of aspartate aminotransferase and γ-glutamyltransferase. The extracts 
contained phenols, tannins, flavonoids, alkaloids, terpenoids, sterols, and reducing 
sugars. Potassium, calcium, and iron levels in the extracts were below the 
recommended daily allowance. In conclusion, the observed hypoglycemic activity 
and slight toxicity could be associated with the phytonutrients present in this plant 
extract. This study recommends continued use of its plant as herbal medicine. 
15. Gupta et al., (2010)[62] studied that Curcumin is a major constituent of rhizomes 
of Curcuma longa. Pharmacokinetic studies of curcumin reveal its poor absorption 
through intestine. Objective of the present study was to enhance bioavailability of 
curcumin by its complexation with phosphatidyl choline (PC). Complex of curcumin 
was prepared with PC and characterized on the basis of solubility, melting point, 
Differential scanning calorimetry, Thin layer chromatography, and Infrared 
spectroscopic analysis. Everted intestine sac technique was used to study ex 
vivo drug absorption of curcumin–PC (CU–PC) complex and plain curcumin. 
Pharmacokinetic studies were performed in rats, and hepatoprotective activity of 
CU–PC complex was also compared with curcumin and CU–PC physical mixture in 
isolated rat hepatocytes. Analytical reports along with spectroscopic data revealed 
the formation of complex. The results of ex vivo study show that CU–PC complex 
has significantly increased absorption compared with curcumin, when given in 
equimolar doses. Complex showed enhanced bioavailability, improved 
pharmacokinetics, and increased hepatoprotective activity as compared with 
curcumin or CU–PC physical mixture.  
16. Ranveer Singh Tomar et al., (2014)[63] Diabetes mellitus is characterised by rise 
in blood sugar levels resulting from insulin dysfunction or insulin insufficiency. Aim: 
The aim of the present investigation is to evaluate antidiabetic activity of 
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hydroalcoholic extract of Annona squamosa Linn (A. squamosa Linn) in alloxan-
induced diabetic rat model. Diabetes is induced by a single-dose intraperitoneal 
injection (i.p.) of alloxan (120 mg/kg) to albino rats. Treatment with A. squamosa 
Linn. extract at a dose of 350 mg/kg and 700 mg/kg and Metformin at a dose of 
5mg/kg for 28 days, after induction of diabetes by alloxan, caused significant 
reduction in blood serum glucose and serum lipid profiles like total cholesterol and 
triglycerides but significant increase in body weight and serum high density 
lipoproteins (HDL) level in diabetic rats compared to untreated group. Histological 
study of the pancreas of diabetic rat treated with A. squamosa extract also showed 
partial regeneration of beta cells. The antidiabetic activity of this extract is found 
comparable to Metformin. Thus, leaves of A. squamosa Linn. can be used as 
potential antidiabetic drug 
17. Yingli Jin et al., (2014)[64] The present study aims to examine the protective 
effect of fenugreek and the underlying mechanism against the development of 
diabetic nephropathy (DN) in streptozotocin- (STZ-) induced diabetic rats. A rat 
model of diabetes was successfully established by direct injection of STZ and then 
the rats were administered an interventional treatment of fenugreek. Parameters of 
renal function, including blood glucose, albuminuria, hemoglobin A1c (HbA1c), 
dimethyl formamide (DMF), blood urine nitrogen (BUN), serum creatinine (Scr), and 
kidney index (KI), were detected in the three groups (Con, DN, and DF). Oxidative 
stress was determined by the activity of antioxidase. Extracellular matrix (ECM) 
accumulation and other morphological alterations were evaluated by means of 
immunohistochemistry and electron microscope. Quantitive (q)PCR was employed to 
detect the mRNA expression of transforming growth factor-β1 (TGF-β1) and 
connective tissue growth factor (CTGF) and protein expression was determined with 
western blot analysis. DN rats in the present study demonstrated a significant renal 
dysfunction, ECM accumulation, pathological alteration, and oxidative stress, while 
the symptoms were evidently reduced by fenugreek treatment. Furthermore, the 
upregulation of TGF-β1 and CTGF at a transcriptional and translational level in DN 
rats was distinctly inhibited by fenugreek. Consequently, fenugreek prevents DN 
development in a STZ-induced diabetic rat model. 
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18. Baynes et al.,(2015)[65] Diabetes Mellitus (DM) is a metabolic disorder 
characterized by the presence of chronic hyperglycemia either immune-mediated 
(Type 1 diabetes), insulin resistance (Type 2), gestational or others (environment, 
genetic defects, infections, and certain drugs). According to International Diabetes 
Federation Report of 2011 an estimated 366 million people had DM, by 2030 this 
number is estimated to almost around 552 million. There are different approaches to 
diagnose diabetes among individuals, The 1997 ADA recommendations for 
diagnosis of DM focus on fasting Plasma Glucose (FPG), while WHO focuses on 
Oral Glucose Tolerance Test (OGTT). This is importance for regular follow-up of 
diabetic patients with the health care provider is of great significance in averting any 
long term complications. 
19.Karthikeyan et al., (2016)[66] Diabetes mellitus is a group of metabolic disorder, 
is characterized by absolute by lack of insulin and resulting in hyperglycemia. About 
2.8% of global populations are affected by Diabetes mellitus. The search for new 
drug with new properties to treat the disease is still in progress. The current review 
have made an attempt to bring together all reported models and advanced 
techniques. Experimentally diabetes mellitus is generally induced in laboratory 
animals by several methods that include: chemical, surgical and genetic 
manipulations. The various in vitro techniques includes: In-vitro studies on insulin 
secretion, In-vitro studies on glucose uptake, Studies using isolated pancreatic islet 
cell lines, Assay of Amylase Inhibition and Inhibition of α-Glucosidase Activity. 
Experimental induction of diabetes mellitus in animal models and in vitro techniques 
are essentials for the advancement of our knowledge, clear understanding of 
pathogenesis and for finding new therapy. The animal models and in vitro techniques 
are essentials for developing a new drug for the treatment diabetes. More animal 
models, advanced techniques have to be developed for advances in diabetes 
research. 
20. Naseer Ali Shah et al., (2014)[67] Reported that the ethyl acetate fraction 
(SCEE) of Sida cordata was investigated for scientific validation of its folk use in 
diabetes. Antidiabetic effect of SCEE was confirmed by antihyperglycemic activity in 
normal glucose loaded and diabetic glucose loaded animals as well as normal off 
feed animals. Confirmation of antidiabetic activity and toxicity ameliorative role of S. 
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cordata was investigated in a chronic multiple dose treatment study of fifteen days. A 
single dose of alloxan (120 mg/kg) produced a decrease in insulin level, 
hyperglycemia, elevated total lipids, triglycerides, and cholesterol and decreased the 
high-density lipoproteins. Concurrent with these changes, there was an increase in 
the concentration of lipid peroxidation (TBARS), H2O2, and nitrite in pancreas, liver, 
and testis. This oxidative stress was related to a decrease in glutathione content 
(GSH) and antioxidant enzymes. Administration of SCEE for 15 days after diabetes 
induction ameliorated hyperglycemia, restored lipid profile, blunted the increase in 
TBARS, H2O2, and nitrite content, and stimulated the GSH production in the organs 
of alloxan-treated rats. He suggested that SCEE could be used as antidiabetic 
component in case of diabetes mellitus. This may be related to its antioxidative 
properties. 
21. Ndidi et al., (2013)[68] reported the tissue-protective potential of Persea 
americana necessitated a look into the histopathological effects of the plant extract 
on the pancreas, liver, and kidneys. This study was conceived and designed based 
on the gaps in the research that has been performed and what is known about the 
plant. The hypoglycaemic and tissue-protective effects of hot aqueous Persea 
americana (avocado pear) seed extracts on alloxan-induced albino rats were 
investigated. Persea americana seeds were extracted using hot water, and different 
concentrations of the extract were prepared. The effects of different concentrations 
(20, 30, 40 g/L) of the hot aqueous P. americana seed extract on alloxan-induced 
Wistar albino rats were compared with those of a reference drug, Metformin. The 
glucose level of the rats was measured daily, and the weight of the animal was 
monitored on a weekly basis for 21 days. The oral glucose tolerance test (OGTT) 
was performed at 0, 30, 60, 90 and 120 minutes, and the histopathologies of the 
liver, kidneys, and pancreas were investigated. Phytochemical analysis of P. 
americana seed extracts indicated the presence of glycosides, tannins, saponins, 
carbohydrates, flavonoids, and alkaloids. The results showed that the extract 
possessed a significant hypoglycaemic (P < 0.05) effect and reversed the 
histopathological damage that occurred in alloxan-induced diabetic rats, comparable 
to the effects Metformin. The seeds of P. americana also had anti-diabetic and 
protective effects on some rat tissues such as the pancreas, kidneys, and liver.  
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22.  Lachin et al., (2012)[69] reported that Diabetes mellitus (DM) is a metabolic 
disorder in the endocrine system resulting from a defect in insulin secretion, insulin 
action or both of them. Adverse side effects of chemical drugs for treatment of 
diabetes persuaded the using of medical plants. Cherry as a traditionally used plant 
for treatment of diabetes, is packed with powerful plant pigments called 
anthocyanins. They give cherries their dark red color and are one of the richest 
antioxidant sources which lower the blood sugar and bear other beneficial health 
effects. The purpose of this study is to evaluate the effect of ethanolic extract of 
cherry fruit on alloxan induced diabetic rats. In this study 36 Male Wistar rats, body 
weight of 150-200gr were divided into 6 groups. Diabetes was induced by intra 
peritoneal injection of 120 mg/kg Alloxan. The duration of the cherries treatment was 
30 days in which single dose of extracts (200mg/kg) were oral administered to 
diabetic rats. Blood glucose levels were estimated with glucometer before treatment, 
2h and 1- 4 weeks after administration of extracts. Treatment with extracts of the 
cherries resulted in a significant reduction in blood glucose and urinary microalbumin 
and an increase in the creatinine secretion level in urea. Extract of this plant is useful 
in controlling the blood glucose level. Cherries appear to aid in diabetes control and 
diminution of the complications of the disease.  
23. Sornalakshmi et al.,(2016)[70]  reported The effect of ethanol extract of whole 
plant of Hedyotis leschenaultiana on Oral Glucose Tolerance was determined. 
Metformin (600μg/kg) was used as reference drug for comparison. Ethanol extract of 
Hedyotis leschenaultiana whole plant was evaluated for Oral Glucose Tolerance 
Test (OGTT) in normal and alloxan induced diabetic rats. Blood glucose 
concentration was evaluated at 0, 30, 60, 90 and 120 minutes after treatment in both 
cases. The extract significantly (p< 0.001) reduced blood glucose level in alloxan 
induced diabetic (hyperglycaemic) rats orally at the dose of 150mg/kg and 300mg/kg 
body weight of ethanol extract respectively. These results suggest that the ethanol 
extract of Hedyotis leschenaultiana whole plant will be useful in the treatment of 
impaired oral glucose tolerance. 
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CHAPTER IV 
AIM AND OBJECTIVE 
4.1. AIM 
The aim of the study is to Prepare and evaluate the Tigonella foenum graceum 
nanophytosomes for Anti-Diabetic activity on Wistar rats. 
4.2. OBJECTIVES 
To emphasize the above aim, I have followed certain objectives 
 Extraction of leaves of Trigonella foenum graceum and its phytochemical 
investigation. 
 Preparation of nanophytosomes of Trigonella foenum graceum. 
 Performing the In vitro and In vivo anti-diabetic activity of Trigonella foenum –
graceum nanophytosomes. 
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4.3. PLAN OF WORK 
The detailed plan of work laid into the following levels, 
I. Collection and Extraction of Trigonella foenum -graceum leaves by using 
water as a solvent 
II. The extracts are concentrated and subjected for preliminary phytochemical 
investigation. 
III. The nano-phytosomes are prepared by using Trigonella foenum -graceum 
leaf extract by thin layer lipid hydration method 
IV. The prepared nano-phytosomes are subjected for Characterization studies 
such as, 
a. Scanning Electron Microscope (SEM) 
b. Fourier Transform – Infra Red Spectroscopy(FT-IR),  
c. Differential Scanning Calorimetry (DSC) 
d. Particle size and Zeta potential(PS & ZP) 
e. Transmission Electron Microscopy (TEM) 
f. X-Ray Diffractometer (XRD) 
V. The Trigonella foenum -graceum nano-phytosomes and aqueous extract are 
subjected for In vitro Anti-Oxidant activity such as, 
o Nitric Oxide Radical scavenging activity (NO) 
o Ferric reducing Anti-Oxidant Power Assay (FRAP) 
o Total Anti-Oxidant activity (TAC) 
VI. The Trigonella foenum -graceum nano-phytosomes and aqueous leaf extract 
are screened for In vitro Anti-diabetic activity  
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VII. The Trigonella foenum -graceum nano-phytosomes and aqueous leaf extract 
are screened for In vivo Anti-diabetic activity by Streptozocin induced diabetes 
rat model. 
VIII.  Bio-chemical studies involves the withdrawing the blood and estimated for 
following parameters like, 
a. Estimation of Super Oxide Dismutase Activity (SOD) 
b. Estimation of Catalase activity (CAT) 
c. Estimation of Reduced Glutathione (GST) 
d. Thio Barbituric Acid Reactive Substances (TBARS) 
IX. Histopathology studies 
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CHAPTER V 
MATERIALS AND METHODS 
 
5.1. MATERIALS 
Cholesterol was obtained from Loba Chem lab Pvt. Ltd., Maharashtra; Egg lecithin is 
obtained from Lipoid pharma Pvt. Ltd., Germany; Chloroform was obtained from 
Sisco Research Laboratories Pvt. Ltd., New Mumbai; Streptozocin was obtained 
from Glenmark Pharmaceuticals Ltd., Goa; Metformin was obtained from Ipca 
Laboratories Ltd., Mumbai; Formalin was obtained from Thermo Fisher Scientific 
India Pvt. Ltd., Mumbai;Fenugreek leaves were collected from local market of 
Rajapalayam. All the chemicals and reagents used in this experiment are of 
analytical grade. 
5.2.1. COLLECTION AND PROCESSING OF TRIGONELLA FOENUM GRACEUM 
PLANT MATERIAL 
Trigonella foenum graceum leaves were collected locally from the Rajapalayam 
market (Virudhunagar Dist,Tamilnadu). The leaves were separated from the plant 
and washed with water and chloroform to remove soil particles, spread them and 
dried in the shade for 7 days. 
 5.2.2. PREPARATION OF LEAF EXTRACT[70] 
The shade dried leaves were subjected to size reduction by trituration  by using 
mortar and pestle to make into fine powder. Weigh required quantity of powder and it 
is dissolved in a requied quantity of boiling water. Then the mixture of powder and 
water is placed in a shaker incubator for 24 hrs.Then it is filtered by using whatmann 
filter paper.Then the filtrate was concentrated on water bath at 400c for 2days.Then 
finally extract was collected and stored at 40c. 
 5.2.3. PRELIMINARY PHYTOCHEMICAL ANALYSIS[71] 
The aqueous extract of leaves ofTrigonella foenum graceum obtained was subjected 
to qualitative analysis to test the presence of various phytochemical like alkaloids, 
flavonoids, steroids, phenols, proteins and amino acids, terpenoids,anthraquinones 
and quinones etc. 
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 A) PROCEDURE 
(I) TEST FOR ALKALAOIDS 
a.) Mayer’s test 
A fraction of extract was treated with mayers test reagent(1.36 g of mercuric chloride 
and 5g of potassium iodide in 100ml water) and observed for the formation of cream 
coloured precipitate. 
b.) Wagner’s test 
A fraction of extract was treated with wagner’s test reagent(1.27 g f iodide and 2g of 
potassium iodide in 100 water)  and observed for the formation of reddish brown 
coloured precipitate. 
c.) Hager’s test 
A few ml of extract was treated with hager’s  test reagent(saturated aqueous solution 
of picric acid)  and observed for the formation of prominent yellow coloured 
precipitate. 
(II) TEST FOR FLAVANOIDS 
a.) NaoH test 
A small amount of extract was treated with aqueous NaoH and HCl,observed for the 
formation of yellow orange colour. 
b.) H2SO4 test 
A fraction of extract was treated with concentrated H2SO4 and observed for the 
formation of orange colour. 
(III) TEST FOR STEROLS 
a.) Liebermann-Burchard test 
A fraction of extract was treated with chloroform,acetic unhydride and drops of 
concentrated H2SO4 was added and observed for the formation of pink or red colour. 
(IV) TEST FOR TERPENOIDS 
a.) Liebermann  test 
A fraction of extract was treated with chloroform,acetic unhydride and drops of 
concentrated H2SO4 was added and observed for the formation of greyish colour. 
(V) TEST FOR PROTEINS AND AMINO ACIDS 
a.) Ninhydrin test(aqueous) 
A fraction of extract was treated with aqueous ninhydrin and observed for the 
formation of blue  colour, indicating presence of amino acids or purple colour 
indicating the presence of protein. 
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b.) Ninhydrin test(acetone) 
Ninhydrin was dissolved in acetone,the extract was treated with  ninhydrin and 
observed for the formation of purple colour. 
c.) Biuret test 
The extract was heated in distiiled water and filtered. The filtrate is treated with 
2%copper sulphate solution,to this added 95%ethanol and potassium hydroxide and 
observed the formation of pink colour.  
(VI) TEST FOR ANTHRAQUINONES 
a.) Borntrager’s test 
About 50mg of powdered extract was heated with 10%ferric chloride solution and 
1ml concentrated HCl. The extract was cooled,filtered and the filtrate was shaken 
with diethyl ether. The ether extract was further extracted with strong ammonia;pink 
or deep red colour of aqueous layer indicate the presence of anthraquinones. 
(VII) TEST FOR PHENOLS 
a.) Ferric chloride test 
A fraction of extract was treated with 5% ferric chloride and observed for the 
formation of deep black or blue colour. 
b.) Liebermann’s test 
The extract was heated with sodium nitrite,added H2SO4 solution diluted with water 
and excess of dilute NaoH was added and observed for the formation of deep red or 
green or blue colour. 
(VIII) TEST FOR QUINONES 
A small amount of extract was treated with concentrated HCl and observed for the 
formation of yellow coloured precipitate. 
B.THIN LAYER CHROMATOGRAPHY [72]: 
Thin layer chromatography (TLC) technique for separation of active compounds was 
carried out by the method of Hao et al. (2004).  Slurry was prepared by mixing 30gm 
of silica gel G with 100ml of water. The slurry was poured into glass plate and the 
slurry was spreaded uniformly on the surface of the glass plate. After setting the 
glass plates were dried in hot air oven at 1100c for 1hr. Baseline was drawn on the 
TLC plate.Small spot of solution containing the sample is applied to a plate and 
dried. Small amount of an appropriate solvent (eluent) Methanol : Chloroform (1:9) 
which shows better separation of compounds,  poured in to a TLC chamber to a 
depth of less than 1 cm. The container is closed with a cover glass or lid and is left 
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for 10 minutes for saturation. The TLC plate is then placed in the chamber and 
allowed to run the chromatogram. The solvent moves up the plate by capillary action 
meets the sample mixture and carries it up the plate (elutes the sample). The dried 
plate is placed in a chamber containing a few crystals of iodine. The iodine vapor in 
the chamber oxidizes the substances in the various spots making them visible to the 
eye. Once the spots are visible they may be outlined with a pencil before the iodine 
coloration fades. 
Rf value   =           Distance travelled by solute 
                Distance travelled by solvent 
 
5.2.4. PREPARATION OF NANOPHYTOSOMES 
 Procedure 
a)THIN LAYER LIPID HYDRATION METHOD[73]: 
Accurately weighed quantity of egg lecithin and cholesterol were  dissolved in 10 ml 
of chloroform in round bottom flask (RBF) and sonicated for 10 min using bath 
sonicator. Organic solvent removal is done by Rotary evaporator (45-50°C). After 
complete removal of solvent thin layer of phospholipids mixture was formed. This film 
was hydrated with Aqueous extract of Trigonella foenum graceum leaves in rotary 
evaporator (37-40°C for 1 hour). After hydration, mixture of lipid and plant extract 
was sonicated for 20 minutes in presence of ice bath for  heat dissipation. Then 
prepared phytosomes were filled in amber colored bottle and stored in freezer (2-
8 0C) until used. 
b) Preparation of phytosome complexes of Trigonella foenum graceum[74] 
The different phytosome complexes of Trigonella foenum graceum  F1, F2, F3 & F4 
containing molar ratio of 1:0.5:1, 2:1:1, 1:0.5:2 and 2:1:2 of Egg lecithin, Cholesterol 
and Trigonella foenum graceum extract were prepared as mentioned in table 6 
Composition of phytosome formulation of aqueous extract of Trigonella foenum 
graceum leaves 
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Table 6: formulation of nanophytosomes 
Phytosomes 
Molar ratio 
(EL:CL:EX) 
Chloroform 
F1 1:0.5:1 10ml 
F2 2:1:1 10ml 
F3 1:0.5:2 10ml 
F4 2:1:2 10ml 
            EL: Egg lecithin CL: Cholesterol EX:Extract 
5.2.5. CHARACTERIZATION OF NANOPHYTOSOMES: 
a)SEM analysis[75] 
Scanning electron microscopy has been used to determine particle size distribution 
and surface morphology of the complexes. Samples were studied using JEOL JSM-
6360 Scanning microscope (Japan).  Approximately 5 μL of the phytosomal 
suspension was transformed to a cover slip, which in turn was mounted on a 
specimen tab. The samples were allowed to dry at room temperature. Then the 
particle size of the formulation was viewed and photographed using Scanning 
Electron Microscope (Sigma, Carl Zeiss). The particles were coated with platinum by 
using vaccum evaporator and thus, the coated samples were viewed and 
photographed in JEOL JSM-6701F Field Emission SEM. Digital images of 
phytosome complex of Trigonella foenum graceum were taken by random scanning 
of the stub at 1000, 5000, 10000 and 30000 X magnifications. 
 b) DSC analysis[75] 
Thermodynamical techniques are applied for determining the thermal stress of 
medicinal compounds of the excipients as well as their interactions during the 
formulation process. The thermal analysis of the Trigonella foenum graceum, 
physical mixture of egg lecithin and cholesterol, physical mixture of egg lecithin and 
cholesterol and phytosome complex of Trigonella foenum graceum were placed in 
the aluminum crimp cell and heated at 10 0C/min from 0 to 4000C in the atmosphere 
of nitrogen (TA Instruments, USA, model DSC Q10 V24.4 Build 116). Peak transition 
onset temperatures were recorded by means of an analyzer. Trigonella foenum 
graceum leaves extract, phospholipon and phytosome were placed in the aluminum 
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crimp cell and heated at 100C/min from 0 to 400 0C in the atmosphere of nitrogen 
(TA Instruments, USA, Model DSC Q10 V24.4 Build 116). Peak transition onset 
temperatures were recorded by means of an analyzer. 
 c) FT-IR analysis[78] 
FT-IR spectral data can be taken to determine the structure and chemical stability of 
pure drug, physical mixture of egg lecithin and cholesterol, physical mixtures and 
nanophytosomal formulations. The spectroscopic evaluation of the formed complex 
can be confirmed by FTIR simply by comparing the spectrum of the complex and the 
individual components and that of the mechanical mixtures. Samples were mixed 
with dry crystalline KBr in a ratio of 1:100 and pellets were prepared. The mixture 
was grounded or triturated into fine powder using an agate mortar before 
compressing into KBr disc. Each KBr disc was scanned at 4 mm/s at a resolution of 
2. FTIR can also be considered as a valuable tool in confirming the stability of the 
phytosomal complex. FT-IR spectra were obtained using a FT-IR spectrometer.  
Spectral scanning can be done in the range between 4000-400 cm-1. 
 d) XRD analysis[77] 
XRD is a unique method in determination of crystallinity of a compound and when 
properly interpreted, by comparison with drug XRD pattern before formulation., 
allows the identification of the drug crystalline changes. XRD was done on pure 
extract, physical mixtures of egg lecithin and cholesterol, physical mixtures and 
phytosome to see the crystallinity in the substance. Sample was scanned in the 
angular range of 50 - 800 in a PHILIPS XPert Pro X-Ray Diffractometer. Dried 
powder sample was kept in sample holder (20 mm × 15mm × 2mm) which was fitted 
into the instrument and X-ray was passed through the sample. 
e) Particle size and zeta potential[76]  
The particle size and Zeta potential of Trigonella foenumgraceum Nano-phytosome 
were assayed by dynamic light scattering (DLS) using a Malvern Zetasizer Nano-ZS 
(Malvern Instruments, Worcestershire, UK). Scattered light was detected at a 173° 
angle. All measurements were performed in the standard suitable conditions to 
validate the results of sample dilution and the constant temperature of 25 °C. 
Furthermore, the apparatus we used systematically and automatically adapts to the 
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sample, the intensity of the laser as well as the attenuator. Therefore, the 
reproducibility of the experimental measurement conditions is ensured. 
 f)TEM analysis[76] 
Vesicles morphology of phytosome was observed visually with a JEOL JEM 1400 
(Japan) Transmission Electron Microscopy (TEM). A total volume of 10 mL sample 
was dispersed before the sample was analyzed. The mixture was then stirred and a 
drop of the sample was placed on the specimen. The 400 mesh grid was placed over 
the specimens and allowed to stand for 1 minute. Residual droplets on the grid were 
cleaned using a filter paper. A drop of uranyl acetate was dropped over the grid and 
the rest of the excess solution was removed using a filter paper. The grid was left for 
30 minutes and the films were then viewed on a transmission electron microscope 
and photographed. 
5.2.6. INVITRO ANTIOXIDANT ACTIVITY OF TRIGONELLA FOENUM –
GRACEUM NANOPHYTOSOMES: 
The following In vitro models were carried out to evaluate antioxidant activity 
 Nitric oxide radical scavenging activity(NO) 
 Ferric Reducing Anti-oxidant Power Assay (FRAP) 
 Total Anti-oxidant activity(TAC) 
a) Nitric oxide radical scavenging activity(NO)[79] 
Nitric oxide (NO) is an important chemical mediator generated by endothelial cells, 
macrophages, neurons, etc. and involved in the regulation of various physiological 
processes.  Excess concentration of NO is associated with several diseases.  
Oxygen reacts with the excess nitric oxide to generate nitrite and peroxy nitrite 
anions, which act as free radical. The Nitric oxide radical scavenging method of 
Trigonella foenum graceum nano-phytosomes and extract was determined method. 
Nitric oxide (NO) radical were generated from sodium nitroprusside solution at 
physiological pH Sodium nitroprusside (1ml of 10mM) were mixed with 1ml of 
Trigonella foenum graceum nano-phytosomes and extract of different concentration 
like 50µg, 100µg, 150µg, 200µg, 250 µg in phosphate buffer (pH 7.4).  The mixture 
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was incubated at 25° C for 150 min. To 1 ml of the incubated solution, 1ml of 
Griess’s reagent (1% sulphanilamide, 2% o-phosphoric acid and 0.1% naphthyl 
ethylene diamine dihydrochloride) was added.  Absorbance was read at 546 nm. 
BHA (Jayaprakasha et.al., 2004) used as a positive control.  % inhibition of OD is 
calculated by using the formula, 
% scavenging  =      A control   - A test  ×100 
                                      A control 
b) Ferric reducing antioxidant power (FRAP) assay[80] 
FRAP assay is based on the ability of antioxidants to reduce Fe3+ to Fe2+ in the 
presence of 2,4,6-tri(2-pyridyl)s-triazine (TPTZ), forming an intense blue Fe2+-TPTZ 
complex with an absorption maximum at 593 nm. This reaction is pH-dependent 
(optimum pH 3.6). The absorbance decrease is proportional to the antioxidant 
content (Benzie and Strain, 1996). 0.2 ml of Trigonella foenum graceum nano-
phytosome and extract is added to 3.8 ml of FRAP reagent (10 parts of 300 mM 
sodium acetate buffer at pH 3.6, 1 part of 10.0 mM TPTZ solution and 1 part of 20.0 
mM FeCl3. 6H2O solution) and the reaction mixture is incubated at 37°C for 30 min 
and the increase in absorbance at 593 nm is measured. FeSO4 is used for 
calibration. The antioxidant capacity based on the ability to reduce ferric ions of 
sample is calculated from the linear calibration curve and expressed as mmol FeSO4 
equivalents per gram of sample. BHA (Benzie and Strain, 1996) used as a positive 
control. 
c) Total Anti-oxidant activity (TAC)[81] 
The total antioxidant capacity of Trigonella foenum graceum nano-phytosomes and 
extract was measured spectrophotometrically by the phosphomolybdenum method, 
which is based on the reduction of Mo(VI) to Mo(V) by the sample analyte and the 
subsequent formation of green phosphate/Mo(V) compounds with a maximum 
absorption at 695 nm. Electron transfer occurs in this assay which depends upon the 
structure of the anti-oxidant. Total anti-oxidant activity was determined for Trigonella 
foenum graceum nano-phytosomes and Extract in terms of mg equivalent of 
ascorbic acid per g crude extract using phosphomolybdate complex assay. 
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5.2.7. INVIVO ANTI –DIABETIC ACTIVITY FOR TRIGONELLA FOENUM 
GRACEUM NANOPHYTOSOMES AND EXTRACT: 
a) Materials: 
Glucometer and stirps to measure blood glucose level, Gloves, Face mask, 
Dissection box, oral needle, sterile cloth, Lancet.,Surgical blade,Insulin 
syringe,Normalsaline. 
b) Animals: 
Healthy Swiss albino rats of either sex weighing 150-200g obtained from the AKCP 
animal house(CPCSEA approval no: 509/02/C/CPCSEA/2018), housed under 
specific pathogen-free conditions were used for the study. The animals were placed 
at random and housed in polypropylene cages and were left 7 days for 
acclimatization to animal room maintained under controlled condition (a 12 h light–
dark cycle at 22±20C and relative humidity of 30-70%). All animals were allowed to 
free access to water and fed with standard commercial pellet diet.  All animals were 
taken care of under ethical consideration as per the guidelines of CPCSEA. The 
Institutional Animal Ethics Committee (IAEC) approved the protocol 
(AKCP/IAEC/02/18-19). All the experimental procedures and protocols used in this 
study were reviewed by the Institutional Animal Ethics Committee .Animals were 
used for anti-diabetic study. 
c) Evaluation of oral glucose tolerance test (OGTT)[70]: 
Initial screening of fractions for hypoglycemic activity was carried out in normal 
healthy rats by conducting OGTT. The OGTT was performed for two different doses 
of Trigonella foenum graceum nanophytosomes (50 and100 mg/kg bodyweight per 
orally) and blood glucose level was measured by one touch glucometer (Accu-check, 
India). After 60 minutes of drug administration the rats were treated with 2g/kg of 
glucose given orally.The blood samples were collected from tail vein at the intervals 
of 0, 30, 60, 90 and120 min  to determine the blood glucose levels.  
d) Induction of diabetes[50]: 
Diabetes was induced by a single intra-peritoneal injection of newly prepared 
Streptozocin(65mg/kg) in normal sterile saline to overnight fasted rats. In order to 
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prevent initial drug induced hypoglycemia, Streptozocin injected animals were given 
with 5% glucose water for 24 h. After three days of STZ administration, rats were 
divided according to their fasting blood glucose levels which showed >200 mg/dl. 
The animals did not show the above blood glucose range is excluded from the study. 
e) Grouping of animals: 
Trigonella foenum graceum leaf extract and nano-phytosomes was evaluated for 
diabetic activity by steptozocin induced diabetes in rat model. Thirty six animals 
(albino rats, 180-250 g) were divided into 6 groups of six each[51].  
Group 1: Control received normal saline (10 ml/kg, p.o.);  Group 2: Negative control 
(Diabetic rat); Group 3: Standard Metformin (250 mg/kg/bd.wt., orally dissolved in 
normal saline); Group 4: Trigonella foenum graceum nano-phytosomes 
(50mg/kg/bd.wt., orally); Group 5: Trigonella foenum graceum nano-phytosomes 
(100mg/kg/bd.wt., orally); Group 6: Trigonella foenum graceum aqueous extract 
(200mg/kg/bd.wt., orally) 
f) Treatment of diabetes: 
For therapy, the streptozocin induced diabetes rat model was treated once daily with 
oral administration of prepared Trigonella foenum graceum nano-phytosomes,  
Trigonella foenum graceum extract and standard drug (Metformin) for a period of 
21days.  
g) Measurement of body weight and blood glucose level: 
Body weight and blood glucose levels were estimated on 0,7,14,21st day after the 
administration of extract orally. The blood glucose levels were measured using blood 
glucose test strips with elegance glucometer. 
 5.2.8. INVITRO ANTI-DIABETIC ACTIVITY: 
a) Experimental procedure for α-amylase inhibition assay[66]: 
A total of 500 μl of test samples and standard drug (100-1000μg/ml) were added to 
500 μl of 0.20 mM phosphate buffer (pH 6.9) containing α-amylase (0.5mg/ml) 
solution and were incubated at 25°C for 10 min. After these, 500 μl of a 1% starch 
solution in 0.02 M sodium phosphate buffer (pH 6.9) was added to each tube. The 
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reaction mixtures were then incubated at 25°C for 10 min. The reaction was stopped 
with 1.0 ml of 3, 5 dinitro salicylic acid colour reagent. The test tubes were then 
incubated in a boiling water bath for 5 min, cooled to room temperature. The reaction 
mixture was then diluted after adding 10 ml distilled water and absorbance was 
measured at 540 nm. Control represent 100% enzyme activity and were conducted 
in similar way by replacing extract with vehicle. 
The concentration of the plant extracts required to scavenge 50% of the 
radicals (IC50) was calculated by using the percentage scavenging activities at five 
different concentrations of the extract. Percentage inhibition (I %) was calculated by 
I % = (AC-AS)/ AC x 100 
Where, 
Ac = Absorbance of the control 
As = Absorbance of the sample 
b) α-Glucosidase Inhibitory Assay[66]:  
The effect of the plant essential oil on α-glucosidase activity was determined 
according to the method described by Kim et al., [12], using α-glucosidase from 
Saccharomyces cerevisiae. The substrate solution p-nitropheynyl glucopyranoside 
(pNPG) (3.0 mM) was prepared in 20 mM phosphate buffer, pH 6.9. 100 μL of α-
glucosidase (1.0 U/ml) was pre-incubated with 50 μL of the different concentrations 
of the extracts (ethanol) for 10 mins. Then 50 μL of 3.0 mM (pNPG) as a substrate 
dissolved in 20 mM phosphate buffer (pH 6.9) was added. to start the reaction. The 
reaction mixture was incubated at 37°C for 20 min and stopped by adding 2 ml of 0.1 
M Na2CO3 The α-glucosidase activity was determined by measuring the yellow 
colored para-nitrophenol released from pNPG at 405 nm. The results (% Inhibition) 
are expressed as percentage of the blank. 
The concentration of the plant extracts required to scavenge 50% of the radicals 
(IC50) was calculated by using the percentage scavenging activities at five different 
concentrations of the extract. Percentage inhibition (I %) was calculated by 
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I % = (AC-AS)/ AC x 100 
Where, 
Ac = Absorbance of the control 
As = Absorbance of the sample 
5.2.9. Biochemical studies 
At the end of 21st day treatment, rats were sacrificed by phenobarbitone anaesthesia 
and blood samples are collected and used for the Bio-chemical assay, 
Histopathological studies, etc. 
Preparation of Serum 
Blood was collected by cardiac puncture. Blood was allowed to flow freely into plain 
bottles. The serum was prepared using standard method as described by Yesufu et 
al.,[51]. Briefly, the method used is as follows. Blood was allowed to clot for 30minutes 
and then centrifuged at 2500rpm for 15minutes and serum was harvested. 
The Bio-chemical estimation which have done are, 
a. Estimation of SuperOxide Dismutase activity (SOD) 
b. Estimation of Catalase activity (CAT) 
c. Estimation of Reduced Glutathione (GST) 
d. Thio Barbituric Acid Reactive Substance (TBARs) 
a) Estimation of Superoxide Dismutase activity (SOD)[82] 
Superoxide dismutase activity was assayed according to the method of Sun et al. In 
this method, xanthine-xanthine oxidase system was used to generate a superoxide 
flux, and nitroblue tetrazolium (NBT) was used as an indicator of superoxide 
production. SOD activity was then measured by the degree of inhibition of the 
reaction unit of enzyme providing 50% inhibition of NBT reduction. Results are 
expressed as U/mL. 
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b) Estimation of Catalase Activity (CAT)[83] 
The catalase activity in serum was determined using the modified method as 
described by Atawodi. Briefly, the method is as follows: serum (10 was added to test 
tube containing 2.80mL of 50mM potassium phosphate buffer (pH 7.0). The reaction 
was initiated by adding 0.1mL of fresh 30mM hydrogen peroxide and the 
decomposition rate of hydrogen peroxide was measured at 240nm for 5min on a 
spectrophotometer. A molar extinction coefficient of 0.041mM−1 cm−1 was used to 
calculate catalase activity. 
c) Estimation of Reduced glutathione (GSH)[84] 
Equal quantity of serum was mixed with 10% trichloroacetic acid and the mixture 
was centrifuged to separate proteins. To, 0.01ml of this supernatant, 2ml of 
phosphate buffer (pH – 8.4). 0.5ml of 5’5 dithiobis (2-nitrobenzoic acid) and 0.4 ml of 
distilled water was added. Mixture was vortexed glutathione was expressed as 
µg/mg of proteins. 
d) Thio Barbituric Acid Reactive Substance (TBARS)[85] 
The Thio Barbituric Acid reactive Substance (TBARS) was estimated as per the 
standard procedure. To each test tube , 0.5 ml of supernatant, 0.5 ml of normal 
saline, 1ml of 20% trichloro acetic acid (TCA) and 0.25ml of TBA reagent (200 mg of 
thiobarbituric acid in 30ml of distilled water and 3oml of acetic acid) were added. The 
test tubes were kept for boiling at 950c for 1 hour. To each test tube, 3ml of n-
butanol was added and mixed well. These test tubes were centrifuged at 3000rpm 
for 10mis. The separated butanol layer was collected and read in a 
spectrophotometer against blank at 535nm. Concentration of Thio barbituric reactive 
substance was expressed in terms of nmol malondialdehyde per mg of protein. 
5.2.10. Histopathological study[86]: 
After blood collection rats were sacrificed for tissue studies. The internal organ   
pancreas were isolated and blotted free of blood, weighed immediately to determine 
relative organs weights and observed for gross lesions. Histological examination was 
performed on the tissue preserved in 10% buffered formalin solution with particular 
emphasis on those which showed gross pathological changes. 
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5.2.11. Statistical analysis 
Results are presented as the mean ± SEM for n = 6 rat/group. All experiments were 
performed in triplicate using a minimum of three replicates. Values are expressed as 
mean ± S.E.M. Data were analyzed by one-way analysis of variance (ANOVA) 
followed by Dunnet’s multiple comparison test using Graph pad prism. The values 
are ****P<0.0001, ***P<0.0005 were considered significant, **P<0.001 when 
compared against control. 
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CHAPTER VI 
RESULTS AND DISCUSSION 
 
6.1. a. PRELIMINARY PHYTOCHEMICAL INVESTIGATION 
The preliminary phytochemical studies reveals that the presence of phenols, tannins, 
flavanoids, and saponins (Table 7). Many plants are now used for the traditional 
treatment of diseases, possibly due to the presence of these phytochemicals, which 
have been reported to possess high medicinal value. Phenols, flavonols, 
proanthocyanidins and flavonoids are very important plant bioactive component 
reported to possess strong antioxidant, antibacterial and numerous biological 
activities. Due to their molecules structures reported to contain a hydroxyl group or 
phenolics ring several studies have indicated that these compounds are very 
effective in scavenging free radicals due to their redox properties, thereby having the 
capacity to link with proteins and bacterial membranes to form complexes. 
Table 7: Phytoconstituents of Trigonella foenum graceum 
S.NO TEST RESULT 
1. TEST FOR CARBOHYDRATES  
 A . Molisch’s test + 
 B. Fehling’s test + 
 C. Barfoed's test + 
 D. Benedict's test + 
2. TEST FOR PROTEINS AND AMINO ACIDS  
 A. Ninhydrin Test + 
 B. Biuret Test + 
 C. .Millon’s Test + 
3. TEST FOR ALKALOIDS  
 A. Mayer's test - 
 B. Dragendroff's test - 
 C. Wagner's test - 
 
 
DEPARTMENT OF PHARMACOLOGY,AKCP Page 59 
 
4. TEST FOR PHENOLIC COMPOUNDS AND 
TANNINS 
 
 A. Braemer’s test + 
5. TEST FOR TERPENOIDS + 
6. TEST FOR FLAVONOIDS  
 A. Shinoda test + 
7. TEST FOR SAPONINS  
 A. Foam test/ Frothing test + 
8. TEST FOR GLYCOSIDES  
 A. Legal’s Test + 
 B. Borntrager’s Test + 
9. TEST FOR PHYTOSTEROLS  
 A..Libermann-Burchard test - 
 B.Salkowski reactions - 
10 TEST FOR GUM MUCILAGE + 
            (+) indicates positive reaction              (-) indicates negative reaction 
6.1. B.THIN LAYER CHROMATOGRAPHY 
To support phytochemical screening, aqueous extract leaves  of Trigonella foenum 
graceum was subjected to thin layer chromatography. The Trigonella foenum 
graceum extract showed two well separated spot in the mobile phase Methanol : 
Chloroform (1:9). TLC findings were in agreement with the data of qualitative 
chemical tests and the spots characteristic for flavonoids were observed. The Rf 
values of the spots from Trigonella foenum graceum were calculated and found in 
iodine vapour as as 0.66 (Figure 7) 
Rf  value of aqueous extract of Trigonella foenum graceum 
Rf value  =   Distance travelled by solute 
   Distance travelled by solvent 
  = 3.3 
     5 
  =        0.66 
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From the present study it is presumed as these compounds might be responsible for 
anti-diabetic activity of plant Trigonella foenum graceum. 
                                                 
  Figure 7 Thin layer chromatography of Trigonella foenum graceum extract 
6.2. PREPARATION AND EVALUATION OF TRIGONELLA FOENUM GRACEUM 
NANO-PHYTOSOMES 
6.2.1. Preparation of phytosomes 
Thin layer lipid hydration method was used. F1 formulation having Egg lecithin : 
Cholesterol : Trigonella foenum graceum extract in the ratio 1:0.5:1 was selected as 
optimized formulation on the basis of morphology and particle size and then 
evaluated further. 
6.2.2. EVALUATION OF TRIGONELLA FOENUM GRACEUM NANO-
PHYTOSOMES 
a. Scanning Electron Microscope analysis (SEM) 
Scanning electron microscopy give important insight into the solid state properties 
and surface morphology of drug and drug complexes. SEM analysis as presented in 
Figure 8 confirms the vesicle size measured by size analyzer  i.e. around 100-600 
nm. The drug particles are associated with the phospholipid forming complexes with 
spherical shape, uniform, regular and rigid vesicles. 
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Figure 8 SEM of Trigonella foenum graceum nano-phytosome 
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b. Differential scanning calorimetry analysis (DSC) 
100.00 200.00 300.00 400.00
Temp [C]
-2.00
-1.00
0.00
1.00
2.00
3.00
mW/mg
DSC
139.47x100COnset
158.49x100CEndset
149.69x100CPeak
-324.60x100mJ
-50.72x100J/g
Heat
File Name: TF 1.tad
Detector: DSC-60
Acquisition Date18/07/13
Acquisition Time11:38:48(+0530)
Sample Name: TF 1
Sample Weight: 6.400[mg]
Annotation:
Thermal Analysis Result
TF 1.tad DSC
 
Figure 9 S-I DSC Trigonella foenum graceum thermogram of extract 
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Figure 10 S-II DSC thermogram of Egg lecithin and Cholesterol 
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Figure 11 S-III  DSC thermogram of physical mixtures of Trigonella foenum 
graceum extract , egg lecithin, cholesterol 
 
DEPARTMENT OF PHARMACOLOGY,AKCP Page 64 
 
Differential scanning calorimetry study was carried out to ensure formation of 
complex between Trigonella foenum graceum extract, cholesterol and egg lecithin, to 
confirm the presence of Trigonella foenum graceum extract in the phytosome. DSC 
thermograms of the pure Trigonella foenum graceum extract, cholesterol and egg 
lecithin, physical mixture of them are shown in Figure 9,10,11 . DSC thermograms of 
Pure Trigonella foenum graceum extract (S I) showed a endothermal peak at 
149.690C and its beginning melting point was 139.47oc, it is attributed to its melting 
point. Egg lecithin and Cholesterol (S II) showed an endothermal peak at 136.53oc. 
DSC thermogram of physical mixture of Trigonella foenum graceum extract, 
cholesterol, egg lecithin (S III) showed a endothermal peak at 134.58oC. The carbon-
hydrogen chain in soya lecithin perhaps happened to be melt, isomerous or the 
crystal changes. The physical mixture of Trigonella foenum graceum extract, 
Cholesterol and Egg lecithin showed a broad endothermal peak at 134.58oc. When 
compare the Trigonella foenum graceum extract (149.690C) with Physical mixture 
(134.58oC) it showed that there is no wide variation between the peaks and the 
difference is within ±20oC. This slight variation in the peaks may be due to the 
physical interact by Hydrogen bonding between-OH group of Trigonella foenum 
graceum extract and polar part of phosphatidylcholine suggested by Beggan et.al., 
(1999). On the other hand, in the Trigonella foenum graceum extract–cholesterol-
egg lecithin complex, the major endothermic peak was observed at 134.58 °C, which 
was different from the peaks of the individual components of the complex. 
Thermogram of Physical mixtures of Trigonella foenum graceum extract, egg lecithin 
and cholesterol interestingly showed disappearance of the endothermic melting peak 
of Trigonella foenum graceum  extract, indicating that Trigonella foenum graceum 
was completely embedded inside the matrix of physical mixture which had different 
thermal properties. The results are depicted in Figure 9,10,11.Hence,DSC studies 
conformed the absence of drug-excipient interactions. 
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c. Fourier Transform Infra Red Spectroscopic analysis (FT-IR) 
 
Figure 12 S-I represents FT-IR spectra of Trigonella foenum graceum extract 
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Figure  13 S-II FT-IR spectra of Physical mixture of egg lecithin and cholesterol 
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Figure 14 S-III Trigonella foenum graceum nano-phytosome 
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Spectroscopic analysis was used in order to identify and diagnose of complex 
formation between phospholipid and Trigonella foenum graceum extract. In FT-IR 
spectroscopy, functional groups and their numbers were identified from the 
frequency of radiation that absorbs infrared spectra which showed the main chemical 
groups in extract and PC as well as the formation of new interactions between them 
in the nano-phytosomes preparation process (Table 8). The FT-IR spectroscopy of 
Trigonella foenum graceum leaf extract (S-I), mixture of Cholesterol and egg lecithin 
(S II), Trigonella foenum graceum nano-phytosome (S-III) are shown figure 12, 13, 
14. Trigonella foenum graceum leaf extract (S-I) shows that the characterstic C-H 
peak at 2939.52 cm-1, C=O peak at 1710.86 cm-1, C-C peak at 1608.63 cm-1, C-C 
peak at 1517.98 cm-1, C-H peak at 1396.46 cm-1, C-N peak at 1242.16 cm-1, C-N 
peak at 1066.64 cm-1. Trigonella foenum graceum nano-phytosomes (S-III) shows 
that the characteristic peak at O-H peak at 3861.49 cm-1, O-H peak at 3836.42 cm-1, 
N-H peak at 3267.41 cm-1, C≡ N peak at 2358.94 cm-1, C≡ N peak at 2335.80 cm-1, 
C≡ N peak at 2227.78 cm-1,  C=C peak at 2013.68 cm-1, C=C peak at 1986.68 cm-
1,C=C peak at 1909.53 cm-1, C=C peak at 1869.02 cm-1, N-H peak at 1637.56 cm-1, 
C-H peak at 1453.16 cm-1, C-C peak at 1412.23 cm-1, C-C peak at 1398.76 cm-1, C-
H peak at 1357.17 cm-1, N-O peak at 1346.78 cm-1, C-N peak at 1220.94 cm-1. Some 
of the peaks of both Trigonella foenum graceum extract and phospholipid were 
shown at their physical mixture spectrum indicating no chemical interaction was 
occurred in this physical mixture. 
Table 8  Interpretation of FT-IR studies 
S.No. 
Functional 
Group 
Wave number (cm-1) 
Reference 
Trigonella 
foenum 
graceum 
Extract 
Phospholi
-pid 
mixture 
Trigonella 
foenum graceum 
nano-phytosome 
1 O-H (stretch) 
Free hydroxyl, 
alcohols, 
phenols 
3640-3610   3861.49 
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2 O-H(stretch) 
Free hydroxyl, 
alcohols, 
phenols 
3640-3610   3836.42 
3 N-H(stretch) 
10,20 
amines,amides 
3400-3250   3267.41 
4 C-H(stretch) 
aromatics 
3100-3000  3020.53  
5 C-H(stretch) 
alkanes 
3000-2850 2939.52 2929.87  
6 CΞN(stretch) 
nitriles 
2260-2210   2358.94 
7 CΞN(stretch) 
nitriles 
2260-2210   2335.80 
8 CΞN(stretch) 
nitriles 
2260-2210   2227.78 
9 C=C(stretch) 
alkenes 
1900-2000   2013.68 
 
10 C=C(stretch) 
Alkanes 
1900-2000  1988.61 1986.68 
11 C=C(stretch) 
alkenes 
1900-2000   1909.53 
12 C=C(stretch) 
alkenes 
1900-2000   1869.02 
 
 
 
DEPARTMENT OF PHARMACOLOGY,AKCP Page 70 
 
13 C=O(stretch) 
aldehyde, 
ketones, 
saturated 
aliphatic 
1665-1740 1710.86 1734.01  
14 C-C(stretch) 
Aromatics 
1600-1585 1608.63  1637.56 
15 C-C(stretch) 
Aromatics 
1500-1400 1517.98  1398.76 
16 C-H(Bend) 
alkanes 
1470-1450   1453.16 
17 C-C(stretch) 
Aromatics 
1500-1400   1412.23 
18 C-H(rocking) 
Alkanes 
1370-1350 1396.46  1357.17 
19 N-O 
Symmetric 
(stretch) nitro 
compounds 
1360-1290   1346.78 
20 C-N(stretch) 
Aliphatic 
amines 
1250-1020 1242.16 1215.15 1220.94 
21 C-N(stretch) 
Aliphatic 
amines 
1250-1020 1066.64 1053.13  
 
Hence,FTIR studies further supported the absence of incompatability between drug 
and excipients. 
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d. Particle size (PS) 
Figure 15 Particle size of Trigonella foenum graceum nano-phytosomes 
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Particle size plays an important role in the stability, availability and organoleptic 
properties of the Nanophytosomal formulation and the particles with smaller size is 
desirable. Results of particle size analysis indicated that nano-phytosomes prepared 
with Trigonella foenum graceum extract and PC possess the particle size in the 
average range of 251nm with polydispersity index of 0.708 (Figure 15). Vesicle size 
tends to increase with increasing concentration of the complex. When the 
concentration of particles is too high, physical interaction either collision or 
electrostatic between vesicles is more pronoun. These interactions alter the 
movement of the particles and produce vesicles with a larger size. The high lipid 
composition in the formulation also increases the tendency for the formation of 
agglomerates, resulting in the bigger size of the vesicles. This indicates the 
uniformity and homogeneity of the size of vesicles in the system. A relative high 
polydispersity index was observed in Trigonella foenum graceum nano-phytosomes 
which may be attributed to high phospholipid content.  
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e. Zeta Potential(ZP) 
Figure 16 Zeta potential of Trigonella foenum graceum nano-phytosomes 
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The Zeta potential is the electric potential in the interface or particle surface and is 
used to predict the stability of colloidal systems. The magnitude of the Zeta potential 
indicates the degree of electrostatic repulsion between adjacent, similarly charged 
particles which affects the stability of colloidal system. Colloids with high absolute 
Zeta potential values (normally  ±30 mV), regardless of their positivity or negativity, 
are electrically stabilized and those with low Zeta potential values are not stable and 
tend to coagulate or flocculate. In general, higher Zeta potential values indicate a 
higher and longer-term stability of the particles. Several factors such as pH, ionic 
strength, type and concentration of the used biopolymers are effective on the Zeta 
potential of the particles. The surface charge analysis results ( -38.6 mV) are shown 
in (Figure 16 ) and point to the physical stability of Trigonella foenum graceum  nano-
phytosomes. 
f)Transmission Electron Microscope (TEM): 
TEM analysis as presented in confirmed the spherical shape of the vesicle. The 
aggregation between vesicles was observed in single particle shape, forming 
irregular large size particles. TEM pictures depicted that the nanophytosomes are 
discretely distributed. Nanophytosomes are nearly spherical in shape with smooth 
surfaces. TEM picture(Figure 17) shows the internal architecture of the 
nanophytosomes. 
 
  Figure 17 TEM analysis of Trigonella foenum-graecum nano-phytosomes 
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F. X-Ray diffaction studies of nanophytosomes 
Presence of single peak at 200 of 2theta indicates lack of crystalinity of the 
nanophytosomes and the absence of sharp peaks inferes the drug become 
amorphous after nanonization process shown in figure 18 
 
 
Figure 18 XRD analysis of Trigonella foenum-graecumnano-phytosomes 
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6.3. SCREENING OF IN VITRO ANTI-OXIDANT ACTIVITY OF TRIGONELLA 
FOENUM GRACEUM  NANO-PHYTOSOMES AND EXTRACT 
6.3.1. Nitric oxide radical scavenging activity 
Nitric oxide is a potent pleiotropic inhibitor of physiological processes such as 
smooth muscle relaxation, neuronal signaling, inhibition of platelet aggregation and 
regulation of cell mediated toxicity. It is a diffusible free radical that plays many roles 
as an effector molecule in diverse biological systems including neuronal messenger, 
vasodilation and antimicrobial and anti tumour activities. Suppression of released NO 
may be partially attributed to direct NO scavenging, as the Trigonella foenum 
graceum nano-phytosomes  decreased the amount of nitrite generated from the 
decomposition of SNP in vitro. The scavenging of NO by the Trigonella foenum 
graceum nano-phytosomes was increased in concentration dependent manner. 
Figure 19 illustrates a significant decrease in the NO radical due to the scavenging 
ability of nano-phytosomes, extract and BHA(Standard Antioxidant). The Trigonella 
foenum graceum  nano-phytosome showed maximum activity of 38.42% at 
250µg/ml, whereas BHA at the same concentration exhibited 41.04% inhibition 
(Table 9). 
Table 9 Nitric oxide radical scavenging activity of Trigonella foenum graceum 
nano-phytosome and extract 
S.No. 
Concentration 
(µg/ml) 
% of scavenging of Nitric oxide radical 
BHA(Butylated 
hydroxy 
Anisole) 
Trigonella 
foenum graceum 
nano-phytosome 
Trigonella 
foenum 
graceum 
extract 
1 50 21.17±0.36 19.03±0.29** 12.96±0.23**** 
2 100 24.85±0.37 21.37±0.33** 16.23±0.42**** 
3 150 31.99±0.44 26.65±0.27**** 20.69±0.24**** 
4 200 36.84±0.22 31.96±0.26**** 25.36±0.32**** 
5 250 41.04±0.46 38.42±0.27** 31.24±0.20**** 
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Values are expressed as mean ± S.E.M. Data were analyzed by one-way ANOVA 
followed by Dunnet’s multiple comparison test. The values are ****P<0.0001, 
***P<0.0005, **P<0.001 when compared against control. 
                     
       Figure 19  represents Nitric oxide radical scavenging activity 
6.3.3. Ferric reducing Anti-oxidant power assay (FRAP) 
FRAP assay measures the reducing potential of an antioxidant reacting with a ferric 
tripyridyltriazine [Fe3+-TPTZ] complex and producing a coloured ferrous 
tripyridyltriazine [Fe2+-TPTZ]11. Generally, the reducing properties are associated 
with the presence of compounds which exert their action by breaking the free radical 
chain by donating a hydrogen atom. Frap assay treats the antioxidants in the sample 
as a reductant in a redox-linked colorimetric reaction. In the present study, the trend 
for ferric ion reducing activities of Trigonella foenum graceum nano-phytosomes, 
extract and BHA are shown in Figure 20 and table 10 . The absorbance of Trigonella 
foenum graceum nano-phytosomes are clearly increased, due to the formation of the 
Fe2+-TPTZ complex with increasing concentration. The Trigonella foenum graceum 
nano-phytosmes and Trigonella foenum graceum extract showed increased ferric 
reducing power with the increased concentration as standard antioxidant. Hence 
they should be able to donate electrons to free radicals stable in the actual biological 
and food system.  
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Table 10 represents FRAP assay of Trigonella foenum graceum  nano-
phytosome and extract 
S.No. 
Concentration 
µg/ml 
OD at 593 nm 
BHA 
Trigonella 
foenum graceum 
nano-phytosome 
Trigonella 
foenum 
graceum 
extract 
1 100 0.351±0.004 0.323±0.003** 0.312±0.004*** 
2 200 0.417±0.004 0.377±0.003*** 0.332±0.004**** 
3 300 0.490±0.003 0.446±0.006*** 0.414±0.004**** 
4 400 0.550±0.003 0.525±0.004** 0.480±0.003**** 
5 500 0.660±0.024 0.606±0.006 0.505±0.004*** 
 
Values are expressed as mean ± S.E.M. Data were analyzed by one-way ANOVA 
followed by Dunnet’s multiple comparison test. The values are ****P<0.0001, 
***P<0.0005, **P<0.001 when compared against control. 
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Figure 20  Ferric reducing Antioxidant power 
6.3.4. Total Anti-Oxidant activity 
Total anti-oxidant activity using phosphomolybdate complex assay of 
Trigonella foenum graceum crude extract and nano-phytosome was 
determined and expressed in ascorbic acid equivalent per gram of extract and 
nano-phytosome. 
Table 11 represents Total Anti-Oxidant activity of Trigonella foenum 
graceum nano-phytosome and Extract 
Total Anti-oxidant activity µ mole of 
Ascorbic acid equivalent per g crude 
extract of Trigonella foenum 
graceum 
171.12±3.56 
Total Anti-oxidant activity µ mole of 
Ascorbic acid equivalent per ml of 
Trigonella foenum graceum Nano-
phytosome 
234.67±2.38 
Values are expressed as mean ± S.E.M. 
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6.4.EVALUATION OF INVIVO ANTI-DIABETIC ACTIVITY 
6.4.1. Effect of Trigonella foenum graceum nanophytomes on Oral 
Glucose Tolerance Test(OGTT) in experimental rats: 
In ogtt test investigation group 1 served as control, group 2 served as 
Trigonella foenum graceum nanophytomes 50mg/kg body weight and group 3 
served as Trigonella foenum graceum nanophytomes 100mg/kg body 
weight.The blood levels of glucose were demonstrated the significant change 
after oral administration of glucose solution.Dose dependent blood glucose 
reduction was observed in rats(group2 and group 3)after treatment with 
Trigonella foenum graceum nanophytomes 50 and 100mg/kg at 0,60,90and 
120 min The results are given below in the table 12 and figure:21 
Table 12 represents oral glucose tolerance test in rats 
Treatment Dose 
Blood glucose level (mg/dl) 
 
 
0 min 
 
30 min 
 
60 min 
 
90 min 
 
120 min 
Group I Normal 
saline 
0.9% 
Nacl 
 
76.54±1 
.45  
 
 
122.78± 
1.87*** 
 
 
137.34± 
1.46***  
 
 
112.66± 
1.05** 
 
 
73.54±3 
.56  
 
Group II 50 
mg/kg 
72.56±0 
.96  
 
112.51± 
1.58** 
 
132.48± 
1.42***  
 
101.22± 
1.07**  
 
70.42±2 
.42  
 
Group III 100 
mg/kg 
78.74±1 
.39  
 
101.87± 
1.43  
 
120.66± 
0.58** 
 
91.43±1 
.68  
 
67.38±2 
.19  
 
Values are expressed as mean ± S.E.M. Data were analyzed by one-way 
ANOVA followed by Dunnet’s multiple comparison test. The values are 
****P<0.0001, ***P<0.0005, **P<0.001 when compared against control. 
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Figure 21: Oral glucose tolerance test 
6.4.2. Effect of Trigonella foenum graceum nanophytomes and its 
aqueous extract on blood glucose level in experimental rats: 
Single dose of streptozocin(65mg/kg) significantly increases the blood 
glucose as shown in table13 and figure 22. After daily administration with 
Trigonella foenum graceum nanophytomes (50 and 100 mg/kg p.o) and 
aqueous extract of Trigonella foenum graceum (200 mg/kg p.o) for 21 days, 
significant decreased in blood glucose levels was observed in diabetic rats. At 
the end of the experiment (21st day) blood glucose level was (145±2.25) mg/dl 
, (123.23±2.4) mg/dl and (148.25±2.33) mg/dl  of the treated groups of doses 
of Trigonella foenum graceum nanophytosomes 50 and 100 mg/dl and 
aqueous extract of Trigonella foenum graceum 200mg/dl respectively. 
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Table 13: represents blood glucose levels in rats 
 
Values are expressed as mean ± S.E.M. Data were analyzed by one-way 
ANOVA followed by Dunnet’s multiple comparison test. The values are 
****P<0.0001, ***P<0.0005, **P<0.001 when compared against control. 
 
Figure 22 Blood glucose level 
 
 
Groups 
Blood glucose level (mg/dl) 
 
Initial day Day 7 Day 14 Day 21 
Group 1 115.27±4.50 113.34±3.80 112.7±5.20 113.82±2.40 
Group 2 253.52±2.45 296.54±4.35 325.36±4.27 389.24±4.34 
Group 3 255.24±2.28 201.23±3.52 130.31±2.34*** 116.42±2.80*** 
Group 4 252.21±2.24 234.20±2.25** 197.20±2.25** 145.22±2.25** 
Group 5 265.52±2.70 226.43±2.90** 158.58±4.30** 123.23±2.41*** 
Group 6 258.23±1.53 236.18±2.10*** 199.24±3.23*** 148.25±2.33** 
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6.4.3.  Effect of Trigonella foenum graceum nanophytomes and its 
aqueous extract on body weight in experimental rats: 
In diabetic rats,continuous reduction of body weight was observed as shown 
in table14 and figure 23 .Metformin(250mg/kg) as well as the 
nanophytosomes(50 and 100 mg/kg) and aqueous extracts treatment 
significantly improved the body weight of diabetic rats. 
                 Table 14: represents body weight in rats 
Values are expressed as mean ± S.E.M. Data were analyzed by one-way 
ANOVA followed by Dunnet’s multiple comparison test. The values are 
****P<0.0001, ***P<0.0005, **P<0.001 when compared against control. 
 
Figure 23: Body weight of rats 
Groups 
Body weight (g) 
Initial day Day 7 Day 14 Day 21 
Group 1 215.20±2.35 222.43±4.22 225.41±3.62 228.47±3.17 
Group 2 224.34±2.70 220.21±2.42 212.25±1.52 207.13±2.48 
Group 3 222.23±2.71 223.22±2.25 225.53±2.54** 227.32±2.43** 
Group 4 226.34±2.32 224.42±2.20** 225.44±3.42 227.23±2.35** 
Group 5 225.24±2.23  224.35±2.32 225.27±1.35** 226.23±1.41*** 
Group 6 228.23±1.53 226.18±2.10** 227.24±3.23** 228.25±2.33** 
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6.5. INVITRO ANTI-DIABETIC ACTIVITY: 
6.5.1. In Vitro α-Amylase Inhibition Study 
The maximum inhibition of Trigonella foenum nanophytosomes was 85.50% 
at a concentration 250 μg/mL. The percentage inhibition ranged from 85.50% 
- 30.83 %. The IC50 values are tabulated. 
Table 15: represents invitro antidiabetic activity by Alpha amylase 
inhibition method 
Sample Concentration(μg) % Inhibition IC50 
 
Trigonella 
foenum graceum 
nanophytosomes 
50 30.83±0.6   
 
140.49±0.33 
100 42.0±0.1  
150 51.1±0.2  
200 63.8±0.1  
250 85.50±0.2  
 
 
 
Figure 24 reprents Alpha amylase inhibitory assay 
6.5.2.In Vitro α-glucosidase Inhibition Study  
The in vitro α-glucosidase inhibitory studies demonstrated that Trigonella foenum 
graceum had α-glucosidase inhibitory activity. The highest concentration 250 μg/ml 
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tests showed a maximum inhibition of nearly 86.52 %. The percentage inhibition 
varied from 86.52 - 33.89 % from the highest concentration to the lowest 
concentration of 50 μg /ml. The IC50 values are tabulated. 
Table 16: represents invitro antidiabetic activity by Alpha glucosidase 
inhibition method 
Sample Concentration(μg) % Inhibition IC50 
 
Trigonella foenum 
graceum 
nanophytosomes 
50 33.89±0.4   
 
128.33±0.12 
100 46.33±0.0  
150 55.61±0.4  
200 70.48±0.2  
250 86.52±0.4  
 
 
Figure 25 represents Alpha glucosidase inhibition assay 
6.6. BIOCHEMICAL ESTIMATIONS 
6.6.1. Estimation of Superoxide dismutase activity (SOD) 
The In vivo antioxidant assay showed that the Trigonella foenum graceum nano-
phytosome and extract increased the activity of serum superoxide dismutase (SOD). 
The SOD catalyzes the dismutation of superoxide to hydrogen peroxide and oxygen, 
thereby reducing the likelihood of superoxide anion reacting with nitric oxide to form 
reactive peroxynitrite. The serum Superoxide dismutase activity of the group treated 
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with 50mg/kg of Trigonella foenum graceum nano-phytosome was significantly 
higher when compared to other treatment groups and the negative control group. 
The increased serum activity of SOD as observed in this study suggest that the 
Trigonella foenum graceum nano-phytosome and extract has an In vivo anti-oxidant 
activity and is capable of ameliorating the effect of ROS in biologic system (Table 
17). 
6.6.2. Estimation of Catalase activity (CAT) 
Catalase is a ubiquitous enzyme that catalyzes the decomposition of hydrogen 
peroxide, a reactive oxygen species, which is a toxic product of both normal aerobic 
metabolism and pathogenic ROS production. The serum Catalase activity of the 
group treated with 50mg/kg of Trigonella foenum graceum nano-phytosome was 
significantly higher when compared to other treatment groups and the negative 
control group. The increased serum activities of catalase as observed in this study 
suggest that the Trigonella foenum graceum nano-phytosome and extract has an 
Invivo anti-oxidant activity and is capable of ameliorating the effect of ROS in 
biologic system. Trigonella foenum graceum nano-phytosome and extract caused a 
significant increase in the levels of bio-markers i.e., increased in the level of 
Catalase in a dose dependent manner. 
6.6.3. Estimation of reduced glutathione (GSH) 
GSH is a major intracellular non protein sulphydral compound and is accepted as the 
most important intracellular hydrophilic antioxidant. Also, GSH acts as a co-substrate 
for GPx activity and as a co-factor for many enzymes, stress resistance of many 
cells is associated with high intracellular levels of GSH. A decreased GSH content 
may predispose the cells to lower defense against condition of oxidative stress 
during several degenerative disease conditions. Trigonella foenum graceum nano-
phytosome and extract caused a significant decrease in the levels reduced 
glutathione when compared to the control group but the serum reduced glutathione 
activity of the group treated with 50mg/kg of Trigonella foenum graceum nano-
phytosome was significantly higher when compared to other treatment groups and 
the negative control group in a dose dependent manner. 
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6.6.4. Estimation of Thio-barbituric acid reactive substance(TBARS) 
The Invivo antioxidant assay showed that the Trigonella foenum graceum nano-
phytosome and extract increased the activity of TBARS. The serum TBARS activity 
of the group treated with 50mg/kg of Trigonella foenum graceum nano-phytosome 
was significantly higher when compared to other treatment groups and the negative 
control group (Table 17). The increased serum activity of TBARS as observed in this 
study suggest that the Trigonella foenum graceum nano-phytosome and extract has 
an Invivo anti-oxidant activity and is capable of ameliorating the effect of ROS in 
biologic system. 
Some of the phytochemical constituents of the extract may be responsible for the 
anti-oxidant activity as demonstrated in our study. Flavonoids or bioflavonoids are a 
ubiquitous group of polyphenolic substances which are present in most plants, 
concentrated in seeds, fruit skin or peel, bark, and flowers. Numerous studies have 
shown that flavonoids possess potent antioxidant activities capable of scavenging 
hydroxyl radicals, superoxide anions, and lipid peroxy radicals. 
Table17 Bio-marker changes 
Treatment SOD (units/ml) 
CAT(µmol/mg 
protein) 
GSH(µmol/mg 
protein) 
TBARS 
(nmol/mg of 
Protein) 
Group 1 11.31±0.13 45.19 ±0.13 83.22±0.23 2.49±0.21 
Group 2 9.18±0.14*** 32.72± 0.29**** 56.53±0.24**** 1.53±0.24** 
Group 3 16.24±0.17**** 54.37±0.31**** 43.36±0.29**** 4.39±0.13**** 
Group 4 18.36±0.22**** 78.72±0.29**** 73.24±0.17**** 4.89±0.04**** 
Group 5 21.41±0.43**** 104.32±0.28**** 79.61±0.29**** 5.62±0.05**** 
Group 6 17.15±0.28**** 81.41±0.30**** 60.19±0.49**** 4.38±0.01**** 
Values are expressed as mean ± S.E.M. Data were analyzed by one-way ANOVA 
followed by Dunnet’s multiple comparison test. The values are ****P<0.0001, 
***P<0.0005, **P<0.001 when compared against control. 
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Figure 26  Estimation of Superoxide dismutase activity (SOD) 
            
             
Figure 27 Estimation of Catalase activity 
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Figure 28 Estimation of Reduced Glutathione (GSH) 
 
                 
Figure 29  Estimation of TBARS 
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6.7. HISTOPATHOLOGICAL STUDIES 
        
             Figure a          Figure b            Figure c 
         
    Figure d          Figure e           Figure f 
Figure 30 Histological features of Rat pancreas 
Histology of pancreas (Figure 30) showed normal acini, and normal cellular in the 
islets of langerhans in the pancreas  of normal control (Figure 30 a). In diabetic 
animals treated extensivedamage to islets of langerhans and reduced dimensions of 
islets were observed in diabetic rats (Figure 30 b) which were restorated toward 
normal cellular population size of islets by Tigonella foenum graceum 
nanophytosomes (50mg/kg and 100mg/kg)(Figure 30 d,e) and Trigonella foenum 
graceum extract (200mg/kg)(Figure 30 f)  and metformin treated groups(Figure 30 c).  
 
                                       
 
 
  
 
 
 
CHAPTER – VII 
CONCLUSION  
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CHAPTER VII 
CONCLUSION 
 
It was clearly understood that, the plant Trigonella foenum graceum is having many 
phyto constituents like Phenols, flavonols, proanthocyanidins and flavonoids which 
are very important plant bioactive components reported to possess strong anti-
oxidant and antidiabetic activities. 
Trigonella foenum graceum nano-phytosome complex was successfully formed by 
thin layer lipid hydration method with sufficient vesicle size, vesicle size distribution. 
Characterization was done by SEM, TEM, DSC, FT-IR spectroscopy, Particle size 
and Zeta potential confirmed that hydrogen bonds or van der Waals force 
contributed in the Trigonella foenum graceum extract and phospholipids 
complexation. From the above studies it was concluded that phytosomes has better 
physical characteristics than that of extract. 
In-vitro studies revealed that Trigonella foenum graceum nano-phytosomes have 
better anti-oxidant, anti-diabetic activity when compared with aqueous extract of 
leaves of Trigonella foenum graceum. 
Diabetes mellitus is a most common endocrine disorder, which affects the people 
worldwide. To control this disorder many allopathic drugs are available .Those drugs 
are often having severe adverse effect, unpredictable cost which pave the way for 
the use of herbal medicines in the treatment of diabetes. In the present study single 
peritoneal injection of Streptozocin induce diabetes within 2-3days.The symptoms 
like elevated in blood glucose level and reduction in body weight gradually improves 
during the treatment of 21 days orally with Trigonella foenum graceum 
nanophytosomes and extract.In this study, we observed that Trigonella foenum 
graceum nanophytosomes significantly improves the conditions of diabetics when 
compared to Trigonella foenum graceum extract. It is concluded that, the anti-
diabetic activity of Trigonella foenum graceum has enhanced by formulating their 
nanophhtosomes. 
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ABSTRACT 
Phytosomes are said to be natural extracts contains plant constituents which are bound in phospholipids mainly 
phosphotidylcholine by producing a lipid stable molecular complexes. This will become better formulation with high grade 
of stability to attain peak pharmacokinetic and pharmacodynamic profiles. Such degree of freedom will pave to chart out 
many therapeutic interventions towards the treatment of most of diseases. Hence, The authors has taken a lead to emphasize 
the importance of phytosomes, its preparations and characterization and also current scenario towards phytosomal technology 
in detailed way. 
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INTRODUCTION 
Phytosomes are said to be containing natural 
herbal formulations. Most of the Plants are having 
medicinal properties due to the presence of many active 
constituents which are mainly the secondary metabolites 
like flavonoids, terpinoids, tannins, glycosides, alkaloids 
etc.  The active constituents present in the plants are 
mostly hydrophilic in nature. The therapeutic efficacy of  
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herbal extracts are quickly destroyed by the enzymes 
present in the intestinal gut. Hence, advanced researches 
are done for the specific site delivery of these plants 
derived products (Middleton and Kandaswami,1994).The 
term “phyto” means plant and “some” means cell like 
(Mukherjee and Wahile,2006). It is also called as 
herbosomes. This is an advanced methodology, where 
extract of the plant or the hydrophilic phytoconstituents 
are mixed with phospholipids to produce more lipid stable 
molecular complexes, thereby it enhances the absorption 
and bioavailability of phytoconstituents (Manach et al,, 
2004; Mascarell, 1993). Phospholipids are naturally used 
as an aid for digestion and act as carriers for both fat 
soluble and water soluble nutrients (Shivan and Kinjal, 
2010). Phytosomes can easily cross the cell membranes 
and also stratum corneum layer of the skin (Bombardelli 
et al., 1989; Bombardelli, 1991; Bombardelli and Spelta, 
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1991; Loggia et al., 1996; Forster et al., 2009; Chanchal 
and Swarnlata, 2008). In the last century numerous 
research have been performed on a lot of plant extracts to 
know their biological importance and their use in 
medicinal field (Middleton and Kandaswami,1994). 
Phytosomes have better ability to penetrate into the 
membrane of the cell and from there  it enter into the cell 
and finally reaching the systemic circulation (Bombardelli 
et al.,1989).
 
 
Phytosome Technology and Its Advantages 
Hydrophilic phytoconstituents has the ability to 
bind with phospholipids. A specified amount of 
phospholipid (phosphatidylcholine) react with the herbal 
extract in a non-polar solvent. The phospholipid 
(phosphatidylcholine) used in this formulation was 
obtained from soybean with both lipophilic (phosphoyidyl 
part) and hydroplilic (choline) portions. The body portion 
has choline group which is hydrophilic and the tail 
portion has phosphotidyl group which is lipophilic in 
nature, thereby the hydrophilic group is encoded within 
the lipophilic group to form a stable complex, phytosomes 
are formed (Goyal et al., 2011; Keerthi et al., 2014).The 
bonds formed are chemical in nature, which in additional 
provides better stability for the drug molecule in complex 
with wide range of advantages (Table 1). 
Phosphatidylcholine used in this formulation has dual 
function, it act as a carrier for drug moiety with 
nutritional value (Amin and Bhat, 2012; Singh et al., 
2013). 
 
Preparation of Phytosomes  
Though there was not enough data available 
throughout the phytosome research, authors tried 
maximum to provide all inputs for the preparation of 
phytosomes. The method for the preparation of 
phytosomes are as follows: In the first step, phospholipids 
are obtained from either natural or synthetic     sources are 
to be dissolved in a organic solvent such as acetone or 
dioxane. To the solution of phospholipids, herbal extract 
is added with constant stirring. Then the solution is 
allowed to evaporate on a spray dryer. The ratio between 
the portions in the range of 0.5 to 2.0 moles but the most 
preferable ratio is1:1(Karimi et al., 2015; Rani et al., 
2007). Thin flim is formed after evaporation of the 
solvent. Futher hydration of the flim leads to formation of 
phytosomal suspension. The formed phytosomes will be 
collected by precipitation technique. The collected 
phytosomes are futher subjected to drying by 
lyophilisation method (Pandey and Patel,2010; Saha et 
al., 2013). The entire preparations are illustrated in 
schematic way for better understanding to the users (Fig 
2). 
 
Characterization and Evaluation of Phytosomes 
             The characterization techniques for the evaluation 
of phytosomes are as follows (Patel et al., 2013) 
Characterization techniques: 
 
Vesicle size and Zeta potential: The particle size and 
zeta potential can be determined by DLS using a 
computerized inspection system (Patel et al., 2004). 
 
Surface morphology analysis: By using scanning 
electron microscopy (SEM) the surface morphology 
analysis of phytosomes can be determined (Tripathy et 
al., 2013). 
 
Transition temperature: By using differential scanning 
calorimetry the transition temperature of the vesicular 
lipid system can be determined. 
 
Surface tension measurement: Du novy ring 
densitometer is used to find out the surface tension 
activity of a drug dissolved in aqueous solution (Pawar 
and Bhangale, 2015). 
 
Entrapment efficiency:  By using ultracentrifugation 
technique the drug entrapment ability of phytosomes can 
be measured (Patel et al., 2004). 
 
Drug content:  Drug content present in the phytosomes 
can be determined by High performance liquid 
chromatographic method or any other spectroscopic 
methods (Bhattacharya, 2009). 
 
Stability studies: Stability studies were carried out for 
two months on the optimized formulation of phytosomes. 
For stability study the optimized formulation were placed 
in humidity chamber (sonar) at 75%RH,45
0
c. After two 
months, the formulation was evaluated for weight 
variation, hardness, friability, disintegration and 
percentage drug content (Kumari et al., 2011). 
 
SPECTROSCOPIC EVALUATIONS 
The spectroscopic evaluation provides more 
information about phytosomes. They are as follows: 
 
FT-IR:The FT-IR spectra data will be taken to determine 
the structure and chemical shift of the extract, 
phosphotidylcholine and phytosomes (Pawar and 
Bhangale, 2015). 
 
1
H-NMR: The 
1
H-NMRspectra is used to determine the 
development of complex formed between active 
phytoconstituents and phosphotidylcholine molecules. In 
non polar solvents, there will be an evident change in 
1
H-
NMR signal commencing from atoms included in the 
complex formation. The signals from protons are 
broadened. In phospholipids there is broadening of signals 
whereas the singlet correlative to the N-                                
trimethyl portion of choline yields an upfield shift 
(Tripathy et al., 2013).
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13
C-NMR: The 
13
C-NMR of phytosomes, when recorded 
at room temperature all the carbons in phytoconstituents 
are unobservable. The signals equivalent to the choline 
and glycerol portion was broadened, whereas some are 
shifted and most of the resonance of the fatty acids chains 
maintains their initial sharp lines (Gupta and Dixit, 2011). 
 
Current Research Towards Nanophytosomes 
Since the phytosomes are novel in upcoming era, 
few extensive studies are done   on      silymarin, grape 
seed extract, quercetin, curcumin etc (Wellington and 
Jarvis, 2001; Hikino et al,1984).Some are enlisted  have 
for the reading: In Schandalik et al., 1992, 1994,  has used 
nine human volunteer patients and tested the 
hepatoprotective activity of silymarin and reported that 
phytosomal form of silybin possess four times greater 
passage through the liver (Schandalik and Perucca,1994; 
Schandalik et al.,1992). In 1993, Mascarella et al, 
conducted similar work by using 232 patients with 
chronic hepatitis and reported the better bioavailability of 
silymarin phytosome[La Grange et al.,1999]. Grape seed 
phytosome is composed of oligomericpolyphenols, 
proanthocyanidins or procyanidins (Vitisvinifera) of 
varying molecular size, complexed with phospholipids. 
The main properties of procyanidin flavonoids are with 
increased antioxidant capacity and stimulation of 
physiological antioxidant defenses of plasma, protection 
against ischemia/reperfusion induced damages in the 
heart, protective effects against atherosclerosis thereby 
offering marked protection for the cardiovascular system 
and other organs through a network of mechanisms that 
extend beyond their great antioxidant potency. In the year  
of 2001, Jhiang prepared herb epimedii 
flavanoidphytosome (EPF). The precipitate was 
investigated and the study showed that the dissolution of 
the precipitate was significantly higher than that of its 
physical mixture and Herba epimedii extract tablets (Jiang 
et al., 2001). In 2005Bombardelliet al, reported that the 
silymarin phytosomes showed much site specific activity 
and a longer duration of action than the single constituent, 
with respect to percent reduction of edema, inhibition of 
myeloperoxidase activity, antioxidant and free radical 
scavenging activity (Bombardelli et al., 1991). In 
2005Maitiet al produced a quercetin phytosome by a 
simple and reproducible method and reported that the 
phytosomal complex shows better therapeutic effect than 
the uncomplexed molecule in rat liver injury induced by 
carbon tetrachloride (Jiang et al., 2001; Maiti et al., 
2005). Maiti et al, 2006, 2007, also developed naringenin 
and curcumin phytosomes in two different studies and 
reported that antioxidant activity of the phytosomal 
complex has better therapeutic efficacy  than that of 
normal one (Maiti et al., 2010). In xiao et al., 2006,  
prepared silymarin phytosomes and studied its 
pharmacokinetics in rats and reported that the 
bioavailability of silybin has increased markedly with 
phytosomal formulations. Hepatoprotective activity of 
silymarin phytosomes was found to be more than 
silymarin alone against aflatoxin B1, as reported by 
Tedescoet al, 2008, after performing the experiment on 
broiler chicks (Tedesco et al., 2004). Hence, In recent 
years much works are going to focus on standardized 
herbal extracts to formulate into more bioavailable 
phytosomes. Extract of Serenoa repens(CO2 extract) 
extract of Vaccinium myrtillus (Fruit extract), extract of 
Coleus forskohlii, Ximenoil and Ximenynic acid extracted 
from Santalum album, Esculoside, glycosylated coumarin 
obtained from Aesculus hippocastanum, Ruscogenins, 
group of saponins extracted from Ruscus aculeatus are 
highly worked upon for better bioavailability through the 
formation of phytosomes by patented process (Acharya et 
al., 2011). 
 
Commercial Products in Market 
To date, very few products has come in to 
market and said to be commercially available. The list of 
available (Table 2) components is enlisted here for 
readers. 
 
Table 1. Advantages of Phytosomes 
SNO 
Advantages of Phytosomes (Kidd and Head, 2005; Semalty et al., 2007; Naik and Panda, 2008; 
Bhattacharya,2009). 
1. Hydrophilic herbal extracts absorption is enhanced and has a better therapeutic effect. 
2. Phytosomes deliver the drug at specific site, so low dose is required to produce therapeutic effect. 
3. Phytosomes are easy to develop and has more stability than any other herbal formulations. 
4. 
The carrier used in this formulation (phosphotidylcholine)has an advantage that it is eco-friendly 
with nutritional value. 
5. Drug entrapment capacity of phytosomes is high than compared to any other herbal formulations. 
6. 
No complex techniques are not required in the production of phytosomes and hence low cost is 
required for its production. 
7. 
Phytosomal formulations are easily penetrate through the layer of the skin. Hence it can use for 
transdermal delivery. 
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Table 2. Commercial products of phytosomes 
S.No Phytosomes Phytoconstituents Therapeutic Applications 
1. 
 
Silybin 
Phytosome 
Silybin from Silybummarianum Hepatoprotective, antioxidant for liver and skin 
2. 
Ginkgo 
Phytosome 
24% ginkgo flavonoids 
Protects brain and vascular linings, anti-skin 
Ageing 
3. 
 
Ginseng 
Phytosome 
37.5% ginsenosides 
Nutraceuticals, immunomodulator 
 
4. 
Green Tea 
Phytosome 
Epigallocatechin Nutraceutical, systemic antioxidant, anticancer 
5. 
Grape Seed 
Phytosome 
Procyanidins Nutraceutical, systemic antioxidant, cardioprotective 
6. 
Hawthorn 
Phytosome 
Flavonoids 
Nutraceutical, cardio-protective and 
antihypertensive. 
7. 
Olive oil 
Phytosome 
Polyphenols Antioxidant, anti-inflammatory, antihyperlipidemic 
8. 
Echinacea 
Phytosome 
Echinacosides Nutraceutical, immunomodulator 
9. 
Centella 
Phytosome 
Terpenes Vein and Skin disorders 
10. 
Palmetto 
berries 
Phytosomes 
Fatty acids, alcohols and sterols Non-cancerous prostate enlargement 
 
Fig 1(A & B). The difference between phytosome and 
liposome. 
 
Fig 2. Schematic illustration of preparation of 
phytosomes. 
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Fig 3. SEM and TEM photograph of phytosomes 
 
 
CONCLUSION 
Phytosomes or herbosomes are said to be 
advances in herbal formulations. Such phytosomal 
technology forms a strong link among conventional and 
novel drug delivery systems. Apart, phytosomes will have 
better pharmacokinetic and pharmacological efficacy. It 
also has better therapeutic effect at low dose to produce 
desired pharmacological effect. Phytosomes have wide 
scope in nutraceuticals and cosmetology. Hence in future, 
nanophytosomes will play an important role in the field of 
drug delivery with high peak values at affordable cost to 
treat many chronic and acute diseases. 
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